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Abstract 
Steroid responsive meningitis-arteritis (SRMA) is a common disease of the dog with no 
specific ante-mortem diagnostic test and management is complicated by the requirement 
for prolonged treatment and the potential for relapse.  The value of immunosuppressive 
prednisolone  has  been  established  but  an  optimal  regime  is  not  described.    The  lack  of 
diagnostic  and  prognostic  markers  makes  management  frustrating.    This  study 
prospectively  evaluates  a  protocol  for  the  use  of  a  prednisolone  monotherapy  in  the 
management  of  SRMA.    The  utility  of  conventional  and  novel  protein  markers  was 
evaluated  by  examining  their  expression  at  various  milestones  in  the  management  of 
SRMA and by comparing this to their expression in other canine inflammatory and non-
inflammatory central nervous system (CNS) diseases. 
 
This prospective study recruited twenty dogs with a clinical diagnosis of SRMA presenting 
to the University of Glasgow Small Animal Hospital between May 2006 and May 2008.  
These  patients  were  enrolled  on  a  strict  prednisolone  regimen  with  serum  and 
cerebrospinal fluid samples taken at key points in the management of this disease. 
 
The protocol was successful at achieving resolution of clinical signs with no relapse in the 
follow up period in all 20 dogs.  Clinical remission was achieved in all cases within 2 
weeks  of  starting  the  protocol.    When  relapse  occurred  during  the  treatment  schedule 
(4/20), restarting the treatment schedule led to resolution of the disease.  The fact that dogs 
did not relapse post-treatment in this study is supportive of the value of this protocol in 
managing SRMA. 
 
Overall,  the  findings  detailed  in  this  thesis  support  the  use  of  an  immunosuppressive 
prednisolone monotherapy in the treatment of canine SRMA.  Acute phase proteins are 
significantly elevated at initial presentation with the remission of clinical signs, induced by 
immunosuppressive  therapy,  reducing  but  not  eliminating  this  increase  in  serum 
concentrations.  APPs are of particular value in the identification of putative relapse.  In 
contrast, serum and cerebrospinal fluid IgA provides valuable information at diagnosis but 
a persistent increase throughout the disease limits their value in the monitoring of therapy.  
This immunoglobulin was found to be also be elevated in the serum and cerebrospinal fluid 
of other inflammatory and non-inflammatory canine CNS diseases.  A robust prognostic 
marker for SRMA remains elusive.   II 
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Chapter I 
 
REVIEW OF CANINE STEROID RESPONSIVE 
MENINGITIS-ARTERITIS 
 
   2 
1.1  Inflammatory Central Nervous System Disease in the 
Dog 
Inflammatory diseases of the central nervous system (CNS) are one of the most common 
causes of neurological dysfunction in the dog (Fluehmann et al., 2006).  Inflammatory 
CNS  disease  can  be  grouped  into  two  broad  categories;  those  of  a  known  infectious 
aetiology  and  those  causing  meningoencephalomyelitis  of  unknown  aetiology  (Tipold, 
1994).    The  latter  group  consists  of  diseases  such  as  granulomatous 
meningoencephalomyelitis  (GME),  steroid  responsive  meningitis-arteritis,  eosinophilic 
meningoencephalomyelitis,  and  the  numerous  breed  specific  meningoencephalitides 
reported (Bailey and Higgins, 1986; Sorjonen, 1990; Tipold et al., 1993; Tipold and Jaggy, 
1994; Flegel et al., 2008; Levine et al., 2008; Higgins et al., 2008; Windsor et al., 2009). 
 
The antemortem diagnosis of canine inflammatory CNS disease remains challenging being 
based  on  a  combination  of  clinical  criteria,  non-specific  laboratory  investigations  and 
exclusion of other diseases.  This has been demonstrated in the largest retrospective study 
of  canine  inflammatory  CNS  disease  to  date  whereby  clinical  distinction  between 
inflammatory CNS diseases and other non-inflammatory CNS diseases was difficult when 
utilising ante-mortem aids such as history, signalment, clinical examination and clinical 
pathology (Tipold, 1995).  For example, the presence of multifocal signs was been reported 
as the diagnostic hallmark of inflammatory CNS diseases (Oliver et al., 1997) yet Tipold 
(1995) found just one third of the 220 dogs retrospectively reviewed to have multifocal 
clinical signs. 
 
Analysis  of  cerebrospinal  fluid  (CSF)  is  instrumental  in  confirming  the  presence  of 
inflammation and is considered the mainstay of diagnosis (Tipold, 1995).  Cerebrospinal 
fluid analysis surprisingly supersedes magnetic  resonance imaging (MRI) in sensitivity 
(Lamb et al., 2005; Bohn et al., 2006).  However, the true sensitivity and specificity of CSF 
analysis in inflammatory CNS disease has not been determined given the difficulties in 
obtaining a definitive diagnosis in every case (Tipold, 1995).  In addition, unperturbed CSF 
parameters  (i.e.  total  nucleated  cell  count  and  total  protein  concentration)  have  been 
described  in  a  number  of  histopathologically-confirmed  inflammatory  CNS  diseases 
(Thomas and Eger, 1989; Demierre et al., 2001; Cherubini et al., 2006; Tipold and Jaggy, 
1994; Cizinauskas et al., 2000; Levine et al., 2008).  Brain biopsy has been suggested as 
the gold-standard ante-mortem diagnostic aid in inflammatory CNS disease but limited   3 
tissue access, risks of morbidity and mortality together with its limited availability mean 
other techniques remain common place (Thomas et al., 1996; Kraft et al., 1997; Troxel et 
al., 2004; Cherubini et al., 2005; Lamb et al., 2005). 
 
These  features  of  inflammatory  disease  are  reflected  in  steroid  responsive  meningitis-
arteritis (SRMA) in that it is a relatively common disease (representing 2% of neurological 
referrals in one study; Flehmann et al., 2006), with no definitive diagnostic test (Tipold and 
Jaggy,  1994),  and  infrequently  causes  disease  without  CSF  perturbations  (Tipold  and 
Jaggy, 1994; Cizinauskas et al., 2000). 
 
1.2  Steroid Responsive Meningitis-Arteritis 
1.2.1  Background 
Steroid responsive meningitis-arteritis (SRMA) in the dog is a well-recognised disease in 
small animal practice (Tipold and Jaggy, 1994).  The disease was first recognised as a 
polyarteritis in young laboratory Beagles in which a predilection for the meningeal vessels 
and coronary arteries was observed (Harcourt, 1978; Brooks, 1984; Hayes et al., 1989).  
Subsequently numerous terms have been used to describe this clinical syndrome: ‘Beagle 
Pain  Syndrome’  (Hayes  et  al.,  1989),  ‘Canine  Pain  Syndrome’  (Burns  et  al.,  1991), 
‘Canine Juvenile polyarteritis Syndrome’ (Felsburg et al., 1992), ‘Necrotizing Vasculitis’ 
(Brooks,  1984),  and  more  recently,  steroid  responsive  meningitis-arteritis  (Tipold  and 
Jaggy, 1994).  The term SRMA is now the most universally accepted name for this disease 
as it describes both the predominant pathology and treatment (Tipold and Jaggy, 1994). 
 
A typical presentation would be a juvenile dog (less than 2 years of age) of medium to 
large breed (often pure-bred) with lethargy, pyrexia, inappetance and some degree of axial 
skeletal pain.  Axial skeletal pain is most commonly evident as reluctance to move, low 
head carriage, cervical or thoracolumbar pain on examination and occasionally an arched 
back  (Figure  1:1  and  Figure  1:2).    Clinical  signs  can  wax  and  wane  over  a  period  of 
months and typically if left untreated the disease can be self-limiting with many dogs over 
the age of two developing an age-resistance to the disease (Scott-Moncrieff et al., 1992).  
A  caveat  to  this  is  the  development  of  neurological  deficits  due  to  progression  of  the 
meningitis into a myelitis or encephalitis (Tipold and Jaggy, 1994; Wrzosek et al., 2009).  
The prognosis in these circumstances is guarded with mortality rates varying from 5% to   4 
100% (Tipold and Jaggy, 1994; Cizinauskas et al., 2000).  If a rapid diagnosis is achieved 
and a rigorous treatment protocol is adhered to then the prognosis for remission is usually 
excellent (Tipold and Jaggy, 1994; Cizinauskas et al., 2000).   5 
Figure  1:1:    A  young  boxer  exhibiting  low  head  carriage  and  an  arched  back;  signs 
consistent with severe cervical pain.   6 
 
 
Figure 1:2:  A young Beagle demonstrating neck and spinal pain manifest by a low head 
carriage and an arched back; signs consistent with steroid responsive meningitis-arteritis.   7 
1.2.2  Aetiology and Pathogenesis 
The  aetiology  of  SRMA  remains  obscure  though  an  immune-mediated  cause  has  been 
suggested by many authors.  The reasons for this are three-fold: high concentrations of 
immunoglobulin A (IgA) are present both in the serum and CSF (Tipold and Jaggy, 1994; 
Tipold et al., 1994), a feature shared with some human vasculitides including Kawasaki 
disease  (Felsburg  et  al.,  1992)  and  Henoch-Schönlein  purpura  (Saulsbury,  2007);  the 
remission of clinical signs on immunosuppressive doses of steroids (Meric et al., 1985); 
and the absence of identifiable infectious organisms further implicates immune-mediated 
disease (Harcourt, 1978; Meric et al., 1985; Meric et al., 1986; Scott-Moncrieff  et al., 
1992; Poncelet and Balligand, 1993; Tipold and Jaggy, 1994).  T cell activation has been 
identified in this disease, indicating exposure to an antigen (Tipold, 2000), however, no 
bacterial or viral agent has been identified and the suspicion is that this may be a self-
antigen. 
 
The pathology is well-described with the most consistent features being a vasculitis of the 
meningeal arteries (Harcourt, 1978), a non-suppurative inflammation within the meninges 
(Meric et al., 1985), and a sub-clinical coronary arteritis (Harcourt, 1978; Spencer and 
Greaves, 1987; Hayes et al., 1989; Scott-Moncrieff et al., 1992; Snyder et al., 1995).  The 
vascular pathology is similar to that found in confirmed immune-mediated vasculitis due to 
immunoglobulin  deposition  in  blood  vessel  walls  (Tipold,  2000).    However, 
immunoglobulin complexes have not been identified in the arterial  walls of dogs with 
SRMA.    On  this  basis it  is  possible  that  the  observed  vasculitis  is  due  to  some  other 
unknown cause (Tipold, 2000). 
 
1.2.3  Signalment 
Specific breeds appear to be predisposed, including beagles (Harcourt, 1978; Meric et al., 
1985),  Bernese  mountain  dogs  (Presthus,  1991),  and  boxers  (Poncelet  and  Balligand., 
1993; Behr and Cauzinille, 2006) with no sex predilection reported.  Young dogs under 
two years are most commonly affected although there are reports in dogs as old as seven 
years  (Tipold  and  Jaggy,  1994)  with  one  study  suggesting  that  resistance  to  relapse 
develops around two years of age (Scott-Moncrieff et al., 1992). 
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1.2.4  Clinical Signs 
The most common clinical signs include stiffness of the gait, cervical pain, lethargy and 
pyrexia.  Cervical pain is most commonly manifested by a low head carriage and arched 
back (Figure 1:1 and Figure 1:2).  Other clinical signs that may be present from time to 
time include thoracolumbar pain, muscle rigidity and/or spasms (myoclonus).  Two forms 
of the disease have been reported; a fulminating acute form characterised by a neutrophilic 
pleocytosis, and a chronic protracted form represented by a mild mononuclear or mixed 
cell  pleocytosis  associated  with  neurological  deficits  reflecting  extension  of  the 
inflammation to contiguous structures (e.g. a myelitis or encephalitis) (Tipold and Jaggy, 
1994).  However, a recent report does indicate that fatal cerebral extension of meningeal 
inflammation is a complication in acute disease (Wrzosek et al., 2009).  Clinical signs 
therefore vary from per-acute onset with rapid progression, through to a more chronic and 
insidious course with episodic signs over a course of time (Tipold and Jaggy, 1994). 
 
1.2.5  Clinical Pathology 
There is no single diagnostic test that can be  used to establish a diagnosis of SRMA.  
Therefore laboratory findings can only indicate the presence of an inflammatory disease 
process and as such are not specific for this condition.  However, in the correct clinical 
circumstances, these laboratory findings are useful for supporting the diagnosis of SRMA. 
 
Haematology may demonstrate evidence of a leucocytosis with left shift (Hayes et al., 
1989).    Biochemistry  may  reveal  a  mild  hypoalbuminaemia  due  to  the  inflammatory 
disease  process,  as  albumin  is  a  negative  acute  phase  protein;  i.e.  its  concentration 
decreases in response to inflammation (Cerón et al., 2005).  Hyperglobulinaemia has been 
reported and is likely to be due to the raised serum IgA concentrations observed in this 
disease (Tipold and Jaggy, 1994; Tipold et al., 1994). 
 
Cerebrospinal fluid analysis is characterised by an increased white blood cell concentration 
(reference range; < 5-8 wbc/µl (0.005 - 0.008 x 10
9/l)) when CSF is collected from the 
cisterna  magna)  (Di  Terlizzi  and  Platt,  2006;  Bathen-Noethen  et  al.,  2008).    A 
predominance of neutrophils in the absence of bacteria is seen in the acute form of the 
disease (Figure 1:3 A and Figure 1:3 B).  However, as the disease progresses, mononuclear 
cells (macrophages, lymphocytes and monocytes) are found in the CSF and therefore the   9 
chronic  form  of  the  disease  demonstrates  a  mixed  cell  pleocytosis  (Figure  1:3  C).    In 
association  with  this  inflammatory  response  an  increase  in  the  CSF  total  protein 
concentration is also expected (a normal CSF protein concentration is considered as < 250 
mg/l if the CSF was collected from the  cisterna magna)  (Di Terlizzi and Platt, 2006).  
Cerebrospinal fluid changes appear sensitive to immunosuppressive steroid administration 
and will be suppressed if the patient is given this medication before CSF collection (Heller 
and Aurora, 2008), although further investigation is required to investigate whether any 
particular cell lines are affected preferentially.   10 
 
 
Figure 1:3:  Cerebrospinal fluid samples from three dogs (A - C) with steroid responsive 
meningitis-arteritis (SRMA).  A number of mature neutrophils with hypersegmented nuclei 
can be seen (black arrows).  A – The cell count of this sample was 418 cells /µl.  A 
predominance of neutrophils is evident.  B – The cell count in this case was 920 cells /µl.  
There are also a small number of macrophages present (white arrow).  C – This sample 
was taken from a dog with the protracted form of SRMA (i.e. the presence of additional 
neurological  deficits).    The  predominant  cell  types  present  are  macrophages  (white 
arrows). Hematoxylin and eosin stain has been used.   11 
 
1.2.6  Investigation and Diagnosis 
The  diagnosis  of  SRMA,  once  other  causes  have  been  ruled-out,  is  based  upon  the 
signalment, history and physical examination in conjunction with an inflammatory CSF 
analysis,  supported  by  haematological  and  biochemical  values.    Important  differential 
diagnoses  for  cervical  pain  in  a  young  adult  dog  include  discospondylitis,  cervical 
instability, neoplasia and trauma (Table 1-1). 
 
A neutral lateral cervical radiograph should always be considered in any dog presenting 
with cervical pain before manipulation of the atlantoaxial joint is performed due to the 
possibility  of  instability  within  this  region.    Conscious  radiographs  are  preferable  if 
instability  is  suspected,  although  radiographs  can  also  be  obtained  under  general 
anaesthesia  provided  careful  handling  is  observed,  particularly  during  intubation.  
Radiography  may  also  allow  evaluation  of  the  intervertebral  disc  spaces  to  look  for 
evidence of disconspondylitis, i.e. radiopaque irregular proliferative lesions located at the 
vertebral end plates (sclerosis) with associated lysis. 
 
Once these procedures have been performed to rule-out instability then it is safe to procede 
with  collecting  a  CSF  sample  from  the  cerebromedullary  cistern  (Figure  1:4).    Other 
notable differential diagnoses for inflammatory CNS disease in dogs under 2 years of age 
include  protozoal  diseases.    Therefore,  in  the  presence  of  inflammatory  CNS  disease 
consideration should be given to evaluation of CSF for the presence of Neospora DNA 
using a polymerase chain reaction (PCR) test.  Bacterial meningitis is uncommon in dogs 
with CSF culture yielding a low sensitivity (Meric et al., 1988; Radaelli and Platt, 2002; 
Tipold, 1995).  It is therefore usually sufficient to rule out a bacterial cause by the absence 
of intracellular or free-living organisms on a smear. 
 
Other  potential  causes  of  inflammatory  brain  disease  include  granulomatous 
meningoencephalomyelitis (GME) and many of the breed specific meningoencephalitides.  
These diseases should be suspected when neurological deficits are present making them 
difficult  to  distinguish  from  the  protracted  form  of  SRMA.    In  these  circumstances, 
advanced imaging studies are recommended to exclude parenchymal CNS involvement. 
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Immunoglobulin A is reported to be increased in both the serum and CSF of dogs with 
SRMA (Tipold et al., 1994).  As previously mentioned the reference range for IgA in 
normal dogs is ambiguous and patients with other inflammatory CNS diseases can cause 
increased IgA concentrations within serum and CSF (Tipold et al., 1994; Tipold et al., 
1995).  Similarly, IgA has also been found to be normal in cases of SRMA (Behr and 
Cauzinille, 2006; Wrzosek et al., 2009).  Therefore diagnosis of SRMA remains tentative 
and the lack of a specific disease marker makes management frustrating.   13 
 
 
Table 1-1  Adapted from S. R. Platt (2004) Neck and Back Pain. In: BSAVA Manual of 
Canine  and  Feline  Neurology.  3rd  edn.  Eds  S.  R.  Platt  and  N.  J.  Olby.  British  Small 
Animal Veterinary Association, p204. 
Differential Diagnosis for Cervical Pain in a Young Dog 
Inflammatory  SRMA, Granulomatous meningoencephalomyelitis, Breed specific 
encephalitis and meningitis, Infectious meningitis/myelitis, 
Discospondylitis, Osteomyelitis, Empyema, Polyarthritis, 
Polymyositis 
Anomalous  Atlantoaxial Instability, Chiari-like Malformations, 
Osteochondromatosis, Perineurial (Tarlov) cysts, Scoliosis/Vertebral 
abnormalities, Syringohydromyelia 
Degenerative  Wobbler syndrome 
Trauma  Fractures/luxations, Severe spinal cord contusions, Traumatic disc 
herniation 
Neoplastic  Brain Tumours – primary or secondary with raised intracranial 
pressure 
Central Nervous System Neoplasia  
•  Intradural/Extramedullary 
•  Extradural 
•  Intramedullary 
Non-Central Nervous System Tumours   14 
 
Figure 1:4:  Cerebrospinal fluid collection performed at the cerebromedullary cistern.   15 
1.2.7  Treatment 
Immunosuppression  is  the  mainstay  of  treatment.    The  protocol  shown  in  Figure  1:5 
describes a regimen involving an immunosuppressive dose of prednisolone (Prednicare
©; 
Animalcare  Limited)  that  is  reduced  slowly  over  several  months  to  the  lowest  dose 
necessary to maintain remission of clinical signs.  The severity of the clinical signs dictates 
the starting dose and many cases are deemed severe enough to start at a dose of 2 mg/kg 
prednisolone twice daily for the first 2 days.  Anecdotally it is recommended to counteract 
the side-effects of this drug by adding in gastroprotectants.  All dogs undergoing treatment 
in our hospital receive sucralfate (Antepsin
©; Chugai Pharma UK Ltd) (1 - 2 g/dog orally 
three times daily), ranitidine (Zantac
©; GlaxoSmithKline) (2 mg/kg orally twice daily) or 
famotidine (Pepcid
©; Merck, Sharp & Dohme Limited) (0.5 - 1 mg/kg orally once daily) 
for the duration of the corticosteroid therapy.  Furthermore gastrointestinal integrity should 
be  evaluated  throughout  the  course  by  client  education  to  observe  for  the  presence  of 
vomiting, inappetance, melaena or haematochezia.  Steroid responsive meningitis-arteritis 
is associated with moderate to severe pain and so analgesia is frequently essential at the 
start of therapy.  Some cases require opioid analgesia due to intractable neck pain for the 
first 24 hours following diagnosis. 
 
Previous studies advocate the use of prednisolone in the treatment of SRMA (Tipold and 
Jaggy,  1994;  Cizinauskas  et  al.,  2000).    The  reported  regime  commences  with 
administration of prednisolone at an initial dose of 4 mg/kg/day.  After two days this dose 
was  reduced  to  2  mg/kg/day  for  two  weeks.    Following  this  the  prednisolone  was 
decreased to 1 mg/kg/day for a further two weeks.  At this time a re-check examination 
was performed in which a CSF sample was obtained.  These re-check examinations were 
performed every 4 weeks until both the neurological examination and CSF sample were 
found to be normal.  At this time the dose of prednisolone was slowly tapered to 0.5 mg/kg 
every alternate day and this was maintained for at least six months. 
 
Cizinauskas and others (2000) report full remission in 8/10 dogs receiving a prednisolone 
based treatment regime with an in protocol case relapse rate of 60%; the treatment regimen 
also included the use of other therapeutic agents.  Consequently only 4/10 cases received a 
prednisolone monotherapy.  Of these ten cases one was euthanased for reasons related to 
the  disease.    Tipold  and  Jaggy  (1994)  describe  a  managed  prednisolone  monotherapy 
protocol, involving adjustment of the prednisolone dose in the light of CSF parameters, 
achieving a case relapse rate of 25%, resolution rate of 60% and a 5% mortality.   16 
 
Management  of  SRMA  involves  monthly  serial  CSF  analyses  and  repeat  neurological 
examinations until the combined results are normal (Tipold and Jaggy, 1994).  Cizinauskas 
and others (2000) report that between four and 12 re-check examinations were required for 
each  of  the  10  dogs  with  SRMA  to  obtain  a  normal  neurological  examination  with 
unperturbed CSF.  This meant that each patient had at least four cerebellomedullary cistern 
punctures  performed  in  order  to  achieve  remission  representing  a  high  intervention 
management  requiring  dedicated  owner  compliance.    Failure  to  comply  with  such  a 
regime, as reported by Tipold and Jaggy (1994), can result in a high mortality rate.  No 
reported alternative method exists that allows modification of the treatment regime based 
on patient response.  It would be of value to identify a parameter that would predict the 
potential for relapse and to establish the success of a strict prednisolone monotherapy that 
caters  for  relapsing  patients.    Ultimately,  this  would  give  a  benchmark  on  which  to 
evaluate  the  requirement  and  success  of  alternative  medications  (monotherapies  and 
multimodal therapies).   17 
 
 
Figure  1:5:    A  suggested  treatment  flow  chart  for  the  treatment  of  steroid  responsive 
meningitis-arteritis  using  guidance  from  previous  studies  (Tipold  and  Jaggy,  1994; 
Cizinauskas et al., 2000).  BID, twice daily; CSF, cerebrospinal fluid; EOD, every other 
day; SID, once a day. 
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Treatment with antibiotics may be necessary if the diagnosis is uncertain or if bacterial or 
protozoal meningitis is suspected.  In this situation a good choice of first-line antibiotics 
would be clindamycin (Antirobe©, Pfizer) (12.5-25 mg/kg orally TWICE DAILY) and 
trimethoprim/sulphonamide (Trimacare©, Animalcare Limited) (15 mg/kg orally THREE 
TIMES DAILY) as they  are believed to penetrate the CNS better than other available 
antibiotics (Friedland and McCracken, 1994).  If antibiotics are used then treatment should 
be continued until a negative CSF culture is confirmed. 
 
1.2.8  Investigating potential markers of SRMA 
Despite wide recognition of the clinical picture of SRMA the aetiology of this disease 
remains obscure.  Diagnosis relies upon a combination of suggestive clinical indices and 
exclusion of other diseases.  No gold-standard diagnostic modality exists to conclusively 
confirm a clinical diagnosis of SRMA.  Relapse is well recognised in this disease and 
prolonged therapy appears to reduce, but does not eliminate, its occurrence (Tipold and 
Jaggy, 1994; Cizinauskas et al., 2000).  No technique has been described for identifying 
when to cease therapy  and serial CSF collections combined with an assessment of the 
patient’s  clinical  signs  remain  the  only  indices  on  which  to  base  modification  of  the 
treatment  regime  (Tipold  and  Jaggy,  1994;  Cizinauskas  et  al.,  2000).    The  iatrogenic 
effects  of  unnecessarily  prolonged  steroid  therapy,  though  generally  reversible,  are 
undesirable (Cizinauskas et al., 2000). 
 
1.2.8.1  Immunoglobulin A 
Immunoglobulin A is a non-specific disease marker within the serum and CSF that is not 
suppressed by clinically effective therapy (Tipold and Jaggy, 1994; Tipold et al., 1994).  It 
has been suggested that IgA CSF and serum levels tend to remain elevated in dogs that 
have  proven  difficult  to  manage  (Tipold  and  Jaggy,  1994;  Burgener  et  al.,  1998).  
However, the relationship between elevated IgA concentrations and relapse has not been 
reported to be a clinically useful guide for the duration of steroid therapy or prognosis in an 
individual (Tipold and Jaggy, 1994; Tipold et al., 1994; Cizinauskas et al., 2000). 
 
The reason for the raised systemic and intrathecal IgA concentration is unknown but the 
phenomenon appears specific to this inflammatory disease in the dog (Tipold and Jaggy, 
1994;  Tipold  et  al.,  1994).    The  literature  on  IgA  demonstrates  that  an  increased   19 
concentration may be found in the CSF of SRMA patients, though this feature is shared 
with other inflammatory CNS diseases giving it a low specificity.  Conversely, serum IgA 
in SRMA is reported to be significantly elevated above the published reference range (10.9 
- 100.1 µg/mL; Tipold et al., 1994) in comparison to other CNS inflammatory diseases 
where concentrations may be normal or only mildly increased (Tipold and Jaggy, 1994; 
Tipold et al., 1994; Tipold et al., 1995).  However, the reported specificity varies, for 
example, Tipold and Jaggy (1994) report it to be 100% but in a later study Tipold and 
others (1995) suggest a figure of 83%.  A report of normal serum IgA concentrations in 
four groups of healthy dogs found a wide range of IgA values (from 6.1 – 973 µg/mL) with 
1/4 groups (a colony of beagles) exhibiting a mean IgA concentration of 113.9 µg/mL 
(Griot-Wenk et al., 1999).  This suggests that the normal reference range for IgA requires 
further  investigation.    However,  the  combination  of  raised  serum  and  CSF  IgA 
concentrations have been suggested to be useful in the diagnosis of SRMA (Tipold et al., 
1995), particularly the chronic form that can be difficult to distinguish from other canine 
meningoencephalitides.    However,  the  normal  reference  range  and  its  sensitivity  and 
specificity in the diagnosis of SRMA needs further investigation. 
 
1.2.8.2  Cytokines 
Increased serum levels of interleukins, including interleukin-6 (IL-6) and tumour necrosis 
factor (TNF-α) have been documented in humans with Kawasaki disease; the disease for 
which SRMA is a model (Lin et al., 1992).  The concentrations of these cytokines were 
measured to investigate their prognostic value.  It was found that higher levels of IL-6, 
intereukin-8 (IL-8) and TNF were present in those children with Kawasaki disease who 
subsequently develop coronary aneurysms when compared to Kawasaki disease patients 
that recover (Lin et al., 1993).  As a result of these investigations work has been performed 
in SRMA to establish the role of such markers in the management of SRMA. 
 
In one study, interleukin-6 and TNF-α were measured in serum from a group of laboratory 
Beagles with suspected SRMA (Hogenesch et al., 1995).  The concentrations of IL-6 were 
increased in Beagles with clinical disease but were reduced (6/12) or undetectable (6/12) in 
the  same  dogs  when  clinical  remission  had  been  achieved  following  prednisolone 
administration.    Interleukin-6  can  cause  fever,  induce  acute-phase  proteins  (APPs)  and 
cause weight loss (Van Snick, 1990).  The significance of the varying concentrations of IL-
6 in clinical remission is unknown.  However, experimental studies reveal that fever is not 
seen until a threshold of IL-6 is achieved.  This was done by serial monitoring of the core   20 
body temperature and serum IL-6 concentrations in dogs that had been challeneged with an 
injection of lipopolysaccharide (LeMay et al., 1990).  Hogenesch and others (1995) were 
able  to  show  that  the  level  of  this  threshold  varied  amongst  individuals  and  IL-6 
concentration had no correlation with the severity of clinical signs.  In this same study 
serum TNF-α was undetectable in both controls and dogs with SRMA.  This finding may 
suggest that TNF-α has no role in the pathogenesis of SRMA. However, systemic TNF-α 
may not be a true reflection of its presence intrathecally and, unlike IL-6, TNF-α peaks 1-4 
hours  post-induction  and  decreases  to  undetectable  concentrations  after  5-6  hours 
suggesting that sampling time is integral to its detection (Hogenesch et al., 1995). 
 
A second study investigated concentrations of IL-8 in the CSF of four patients with SRMA 
throughout  the  course  of  the  disease  (Burgener  et  al.,  1998).    Interleukin-8  remained 
elevated throughout the disease  and correlated  with concentrations of  IgA in the CSF.  
Three  of  the  four  dogs  had  persistently  high  CSF  IL-8  and  IgA  concentrations  during 
therapeutic management of the disease and this was associated with frequent and severe 
relapse.    The  fourth  dog,  however,  had  elevated  concentrations  of  both  of  these  CSF 
markers and yet responded to a tapering prednisolone regime as described by Tipold and 
Jaggy (1994) without experiencing relapse.  The conclusions from this study remarked that 
IL-8 and IgA may both increase in response to a stimulus or that IL-8 may trigger the 
production of IgA. 
 
1.2.8.3  Acute Phase Proteins 
The  acute  phase  response  provides  markers  for  diagnosing  and  prognosticating 
inflammatory diseases in both humans and dogs (Jergens et al., 2003; Vermeire et al., 
2004; Agrawall, 2005; Mischke et al., 2007).  Serum APP concentrations have been found 
to be eight times more sensitive to inflammatory disease than white blood cells (Cerón et 
al., 2005).  In a study investigating milk SAA concentration in cattle with mastitis it was 
found that maximum values of SAA preceded that of somatic cell count (SCC) and clinical 
signs during both episodes of mastitis recorded in one of the four cows studied (Figure 
1:6).  The situation for the remaining three cases was slightly more complex, and although 
SAA did not reach maximum values before the detection of clinical signs, they increased 
in concentration either prior to or in conjunction with SCC.  A further study established 
that in the early stages of infection serum c-reactive protein (CRP) increases before an 
elevated  rectal  temperature  is  observed  in  cattle  (Saini  et  al.,  1991).    These  findings   21 
suggest that APPs may  provide valuable information in reaching an early diagnosis of 
SRMA and allow the clinician to respond quickly to relapse.   22 
 
Figure 1:6:  Profiles for somatic cell count (SCC) and serum amyloid-A (SAA) in milk in 
a post-parturient cow.  Clinical mastitis (caused by Streptococcus uberis) developed on day 
8 and again on day 16 (as indicated by the blue arrows) (from Hogarth, 2004).   23 
1.3  Acute Phase Response 
1.3.1  Background 
The acute phase response (APR) is a non-specific inflammatory response affecting various 
host organs, that commences within hours of any tissue injury and can last for several days 
(Cerón et al., 2005).  The stimulus resulting in this APR may include bacterial infection, 
trauma, neoplasia, tissue infarction, and immune-mediated inflammatory disease amongst 
others (Murata et al., 2004).  All of these conditions induce a local inflammatory response 
and  the  early  release  of  soluble  mediators,  which  in  turn  leads  to  a  systemic  APR 
encompassing metabolic and physiological changes, providing the host with an optimal 
“infection-fighting” environment.  The proposed purpose of the APR is to prevent ongoing 
tissue damage, to isolate and destroy the infective organisms, to remove harmful molecules 
and debris, and to activate the repair processes that are necessary to return the organ to 
normal function (Baumann and Gauldie, 1994). 
 
The APR is an adaptive response that helps host survival and aims to restore physiological 
homeostasis, as deviations from a normal internal environment can impose a serious threat 
to the health of an individual.  The APR may be relatively transient, subsiding over 24 to 
48 hours, with the host returning to normal function within a few days, demonstrating the 
protective and homeostatic nature of this host response.  In contrast, chronic disease can 
result in a more persistent APR (Baumann and Gauldie, 1994).  Clinical changes observed 
in  these  homeostatic  mechanisms  during  the  APR  include  pyrexia,  lethargy,  anorexia, 
increased  synthesis  of  certain  endocrine  hormones,  decreased  erythropoiesis, 
thrombocytopenia,  alterations  in  plasma  cation  concentrations,  inhibition  of  bone 
formation,  negative  nitrogen  balance  (as  a  result  of  proteolysis  and  decreased  protein 
synthesis  in  skeletal  muscle)  with  consequent  gluconeogenesis,  and  alterations  in  lipid 
metabolism (Cerón et al., 2005). 
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1.3.2  Acute Phase Proteins 
Acute  phase  proteins  (APPs)  are  part  of  the  host  response  to  challenges  such  as 
inflammatory, infectious, traumatic or neoplastic stimuli.  Their expression is moderated 
by  the  release  of  pro-inflammatory  cytokines  either  in  a  positive  (positive  APPs)  or 
negative (negative APPs) manner, or in an alteration of the protein isoform (Murata et al., 
2004; Cerón et al., 2005).  The majority of APPs are synthesised in the liver and released 
into the blood stream.  However, extra-hepatic production sites have been identified for C-
reactive protein (CRP) (Jabs et al., 2003), serum amyloid-A (SAA) (Liang et al., 1997; Lin 
et al., 2001; Eckersall et al., 2001), alpha-1-acid glycoprotein (AGP) (Gahmberg et al., 
1978;  Fournier  et  al.,  2000,  Poland  et  al.,  2002),  and  haptoglobin  (Hp)  (Dobryszycka, 
1997;  Ebersole  et  al.,  2000)  although  the  significance  and  extent  of  this  non-hepatic 
expression is unknown. 
 
Acute phase proteins can be divided based on their response to stimulation with positive 
APPs increasing in response to a stimulus and negative APPs decreasing in concentration 
(Cerón et al., 2005).  Positive APPs are further divided into two groups.  Major APPs have 
very low or undetectable levels in the serum of healthy animals, but increase more than 
100 fold during an APR (Cerón et al., 2005).  Minor or moderate APPs are present in the 
serum of healthy animals and their concentrations do increase during an APR, but only an 
increase of up to 10 fold is observed (Gruys et al., 1994; Eckersall, 1995b).  In humans, the 
concentration of SAA and CRP can increase up to 1000-fold during acute disease states 
(Cerón et al., 2005).  Consequently these proteins are of diagnostic interest in human and 
veterinary medicine. 
 
It is now recognised that there is considerable variation among species in the pattern of the 
APR  (Eckersall,  1995b).    An  early  indication  of  this  inter-species  variation  was  the 
observion that some APPs originally identified in man did not give a similar response in 
animals.    For  example,  the  response  of  CRP  in  cattle  is  different  in  that  it  acts  as  a 
moderate APP.  In contrast, Hp is a major APP in cattle with levels increasing from being 
undetectable in normal animals, to over 100-fold on stimulation (Eckersall 1995a).  In 
dogs, Hp acts as a constitutive serum protein and is a moderate APP (Conner et al., 1988; 
Eckersall et al., 1996).  The pattern of the APP response of selected species is summarised 
in Table 1-2.   25 
 
Acute Phase Protein  Major  Moderate  Minor  Negative 
C-Reactive Protein  Canine, Porcine    Bovine   
Alpha-1-Acid 
Glycoprotein    Bovine, Ovine, 
Canine, Feline  Porcine   
Serum Amyloid-A  Bovine, Canine, 
Feline, Porcine       
Haptoglobin  Bovine, Ovine 
Porcine, 
Canine, Murine, 
Rat 
   
Fibrinogen    All species     
Albumin        All species 
Table 1-2:  Classification of the acute phase protein response in selected species (adapted 
from  Murata  et  al.,  2004;  Cerón  et  al.,  2005).    Major  =  10  to  several  hundred  times 
increase, moderate = 5 to 10 times increase, minor = 1 to 5 times increase, negative = 
decrease.   26 
1.3.3  C-reactive Protein 
C-reactive protein (CRP) was the first APP to be described.  It was identified in humans 
suffering  from  infections  and  named  after  its  ability  to  precipitate  pneumococcal  C-
polysaccaride (Tillett and Francis, 1930).  It has a molecular weight of 100 kD and consists 
of 5 subunits of 20 kD each.  The major difference between human and canine CRP is that 
the canine form has glycosylation of 2 of the 5 subunits and this may be the reason as to 
why  using  antibodies  against  human  CRP  to  measure  canine  CRP  causes  problems 
(Eckersall  and  Conner,  1988).    The  most  established  biological  role  for  CRP  is  in 
complement activation and opsonisation (Volanakis, 1982). 
 
In  human  medicine,  some  authors  have  suggested  CRP  is  a  reliable  indicator  for 
distinguishing bacterial from viral meningitis.  As an example, bacterial meningitis results 
in a significantly elevated serum concentration of CRP whereas no changes are seen in 
viral meningitis (Peltola, 1982). 
 
1.3.4  Serum Amyloid A 
Serum amyloid A,  a 15 kD apolipoprotein is the precursor of the Amyloid A protein, 
which is the principal component of secondary amyloid plaques, which may be deposited 
in major organs as an occasional consequence of chronic inflammatory disease (Husebekk 
et al., 1986).  During inflammation SAA associates predominantly with the third fraction 
of high-density lipoprotein (HDL3) (Benditt et al., 1979), and constitutes as much as 30-
50% of HDL3 protein during the APR.  Serum amyloid A is synthesised primarily by the 
liver although a number of extra-hepatic sites have been shown to exist (Lin et al., 2001; 
Eckersall et al., 2001). 
 
The  structure  of  SAA  has  yet  to  be  determined  (Uhlar  and  Whitehead,  1999).    Few 
attempts  have  been  made  to  elucidate  the  role  of  SAA;  thus  the  normal  physiological 
function of SAA remains unclear.  However, a high degree of conservation of the SAA 
genes and proteins has been maintained throughout the evolution of mammals suggesting 
they have an important biological role, perhaps in survival of the species (Hulten et al., 
1999) in the face of infection by pathogens.  One isoform of SAA (SAA3) is constitutively 
expressed in a number of diseased tissues, in particular endothelial cells, suggesting SAA 
plays an important role in the local defence mechanisms against invading micro-organisms   27 
(Meek et al., 1994; Urieli-Shoval et al., 1998).  Serum amyloid-A has been shown to work 
as scavenger of potentially dangerous oxidised cholesterol but also has immunomodulatory 
activities (He et al., 2006). 
 
1.3.5  Alpha-1-Acid Glycoprotein 
Alpha-1-acid  glycoprotein,  previously  known  as  orosomucoid,  belongs  to  the  lipocalin 
family, a group of extracellular binding proteins specific for hydrophobic molecules, and 
specifically  to  the  immunocalin  subfamily,  which  includes  proteins  with 
immunomodulating  properties  (Lögdberg  and  Wester,  2000).    Human  AGP  has  a  low 
molecular  weight  (41–43  kDa),  high  solubility,  and  high  percentage  of  carbohydrates 
(45%)  (Hochepied  et  al.,  2003).    Its  glycosylation  pattern  is  very  variable  (12–20 
glycoforms) depending on the physiological or pathological conditions, such as parturition, 
inflammation or neoplasia (Biou et al., 1991; Kim and Varki, 1997).  AGP synthesis is 
mainly by hepatocytes, but extrahepatic synthesis has also been reported (Gahmberg et al., 
1978; Fournier et al., 2000, Poland et al., 2002). 
 
The function of AGP has not been completely defined although an immunomodulatory and 
anti-inflammatory  role  is  suggested  as  it  can  down-regulate  neutrophil  responsiveness, 
stimulate  IL-1R  antagonist  secretion  by  macrophages,  inhibit  platelet  aggregation  and 
lymphocyte proliferation, and modulate the production of anti-inflammatory cytokines by 
peripheral blood leucocytes (Hochepied et al., 2003). 
 
Current  veterinary  literature  on  AGP  is  restricted  to  its  diagnostic  use  in  two  chronic 
inflammatory diseases; feline infectious peritonitis (Duthie et al., 1997) and ovine caseous 
lymphadenitis (Eckersall et al., 2007) reflecting its role as a moderate APP. 
 
1.3.6  Haptoglobin 
Haptoglobin is a major plasma glycoprotein synthesised in the liver and is present in most 
body  fluids  (serum,  urine,  saliva,  cerebrospinal  fluid,  amniotic  fluid,  ascites,  etc)  of 
mammals.  It binds free haemoglobin (Hb) in the cardiovascular system of mammals.  The 
binding of Hb to Hp is the strongest non-covalent interaction known among the transport 
proteins in plasma and is not reversible (Yang et al, 1993).  After Hp has bound free Hb,   28 
the complex is degraded by hepatic lysosymes leading to a decrease of Hp concentration in 
plasma  following  haemolysis.    This  reduction  in  Hp  concentration  can  be  profound  in 
severe haemolysis (Yang et al., 2003). 
 
As  a  positive  acute  phase  reactant,  its  plasma  concentration  is  increased  during 
inflammation,  infections  of  different  aetiology,  trauma,  tissue  damage  and  malignancy 
(Dobryszycka,  1997).    Haptoglobin  is  classified  as  a  scavenger  protein  due  to  its 
involvement in the clearance of potentially toxic products (Dennis, 2001).  Haemoglobin 
(Hb)  released  from  ruptured  red  blood  cells  is  toxic  unless  rapidly  cleared  from  the 
circulation (Dennis, 2001).  In the normal situation, ageing red blood cells are degraded in 
the bone marrow, liver or spleen however in certain circumstances, such as infection or 
inflammatory disorders, red cells may burst within blood vessels.  The plasma protein Hp 
is thought to be involved in promoting the clearance of plasma Hb because it strongly 
binds free Hb and is depleted during haemolysis (Kristiansen et al., 2001).  Consequently it 
is  hypothesised  that  Hp  also  has  a  similar  role  with  regards  to  scavenging  other 
inflammatory byproducts (Dennis, 2001). 
 
1.3.7  Functions of Acute Phase Proteins 
Although several functions have been ascribed to the APPs, speculation still surrounds this 
topic with regard their absolute role(s).  In general, the APPs have a variety of roles in 
inflammation  acting  as  mediators  of  cytokines  as  well  as  scavengers  of  cell  derived 
products released from damaged tissue or macrophages (Dennis, 2001).  In addition, some 
members  of  the  family  may  influence  the  immune  response,  which  often  accompanies 
inflammation and the release of autologous antigens, through direct protection of the host 
(Thompson  et  al.,  1992).    For  example,  the  binding  of  free  Hb  by  Hp  restricts  the 
availability of free iron to invading bacteria (Dobryszycka, 1997).  The fact that APPs have 
been  conserved  throughout  evolution  and  that  they  are  induced  in  large  amounts  in 
response to harmful stimuli infers that they have a positive input to inflammatory  and 
tissue repair processes (Hulten, et al., 1999). 
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1.3.8  Initiation and Progression of Acute Phase Response 
Following the discovery of CRP in the 1930s, APPs were used as markers of inflammation 
for many years, however, from the 1980’s, research concentrated on the regulation of APP 
biosynthesis (Kushner, 1982).  In vitro models confirmed that the circulating mediators 
capable  of  hepatocyte  stimulation  following  local  tissue  injury  were  small  hormonal 
proteins called cytokines.  Cytokines are intercellular signalling polypeptides produced by 
a number of different cells, but the most important sources are tissue macrophages and 
blood  monocytes  at  sites  of  inflammation.    Mononuclear  cells  are  most  commonly 
associated  with  initiating  the  cascade  of  events  during  the  APR.    Pro-inflammatory 
cytokines including interleukin-1 (IL-1), interleukin-6 (IL-6) and tumour necrosis factor–α 
(TNF-α)  are  released  from  activated  macrophages  and  monocytes  at  the  site  of 
inflammatory lesions or infection (Heinrich et al., 1990) and are the major mediators of the 
APR in the liver.  During the hepatic APR, these pro-inflammatory cytokines enhance the 
expression and secretion of plasma proteins, namely the positive APPs and decrease the 
expression  and  secretion  of  the  negative  APPs.    The  early  release  of  these  pro-
inflammatory  cytokines  acts  to  notify  the  immune  system  through  local  and  distant 
activity.  At the local reaction site cytokines activate stromal cells e.g. fibroblasts and 
endothelial cells causing a secondary release of cytokines (Baumann and Gauldie, 1994).  
This results in the systemic release of cytokines and initiates a signal transduction cascade 
ultimately leading to the systemic APR.  Many cytokines can regulate the production of 
other cytokines and their receptors meaning combinations of cytokines may be additive, 
inhibitory, synergistic, or cooperative in their actions (Gabay and Kushner, 1999).   30 
 
1.3.9  Applications of Acute Phase Proteins in Veterinary Medicine 
The possible diagnostic use of APPs in veterinary medicine has been comprehensively 
reviewed (Eckersall and Conner, 1988; Kent, 1992; Gruys et al., 1994; Eckersall, 1995b; 
Pedersen et al., 2004; Murata et al., 2004).  Serum CRP has been found to increase rapidly 
in dogs with arthritis (Ohno et al., 2006), lymphoma (Nielsen et al., 2007), inflammatory 
bowel disease (Jergens et al., 2003), haematological diseases (Tecles et al., 2005), and in 
many infectious diseases there is growing evidence for the utility of these proteins in a 
wide range of conditions (Cerón et al., 2005; Paltrinieri, 2007). 
 
As well as markers of infection or inflammation, APPs may also serve as indicators of 
prognosis  and  progress  of  the  animal  in  response  to  treatment  (Jergens  et  al.,  2003; 
Vermeire et al., 2004; Agrawall, 2005; Mischke et al., 2007).  The evidence that serum 
APP concentrations correlate with the markers of certain diseases (e.g. somatic cell count 
and  mastitis,  Hogarth,  2004)  and  return  to  control  ranges  faster  than  these  established 
markers suggest that APP concentrations may be valuable in the early identification of 
disease remission and early convalescence.  An example of this is in canine multicentric 
lymphosarcoma  where  decreased  serum  CRP  and  AGP  concentrations,  compared  with 
pretreatment  concentrations,  have  been  shown  to  be  indicative  of  remission  after 
chemotherapy in dogs with multicentric lymphosarcoma (Hahn et al., 1999; Nielsen et al., 
2007).  Another example of this is in dogs with leptospirosis where an increased ratio of 
CRP  to  haptoglobin  was  found  to  be  significantly  associated  with  a  negative  outcome 
(Mastrorilli et al., 2007). 
 
Another  important  feature  of  the  APR  in  different  diseases  is  their  variable  response 
depending on the disease in question.  For example, chronic conditions such as canine 
lymphosarcoma  (Merlo  et  al.,  2007)  are  characterised  by  continued  synthesis  of  these 
proteins during periods of disease quiescence or remission (Eckersall, 2004).  In contrast, 
dogs with immune-mediated haemolytic anaemia, having survived their acute illness and 
achieved disease remission, have serum concentrations of CRP, SAA and AGP within the 
reference  range  (Zoia  and  Morris,  2007).    Furthermore,  the  outcome  of  the  dogs  that 
achieved  unperturbed  APP  concentrations  was  mixed  with  some  patients  clincially 
resolving  after  prednisolone  treatment  and  others  exhibiting  relapse  later  on.    The   31 
implication of this observation on the necessity for chronic immunosuppression remains to 
be investigated (Eckersall, 2004). 
 
1.4  Preparatory Work 
Before commencing this study little was known regarding the APR in SRMA.  Increasing 
evidence suggested that a systemic inflammatory response coincided with the acute clinical 
signs seen in each patient.  The occurrence of an APR in canine SRMA is supported by the 
findings  of  moderate  to  marked  leucocytosis  with  left  shift  (Hayes  et  al.,  1989)  and 
changes in the serum concentrations of several APPs including albumin and CRP (Bathen-
Noethen et al., 2008). 
 
Relapse is an unpredictable and inconvenient complication of SRMA management and 
infrequently  causes  disease  without  CSF  perturbations  (Tipold  and  Jaggy,  1994; 
Cizinauskas et al., 2000).  Acute phase proteins may be of use in these difficult cases and 
may also allow identification of the propensity for a patient to relapse. 
 
Serial monitoring of APPs in dogs with SRMA and study of their association with disease 
severity, response to treatment and prognosis have not been reported.  The possibility that 
there is an alteration in disease markers between convalescence and quiescence in SRMA 
and that the expression intensity of this alteration varies between individuals suggests the 
possibility that these markers may predict disease severity.   32 
1.5  Aims of this Thesis 
The major aims of the present study are three-fold: 
1.  To describe acute phase protein markers related to the diagnosis and management 
of SRMA as a first step towards confirming them as diagnostic and prognostic 
markers. 
2.  To investigate in detail the utility of immunoglobulin A as a diagnostic tool. 
3.  To implement and prospectively evaluate a refined prednisolone treatment protocol 
in the management of SRMA.   33 
 
Chapter II 
 
MATERIALS & METHODS  
   34 
 
2.1  Collection of clinical material 
2.1.1  Case selection 
2.1.1.1  Steroid Responsive Meningitis-Arteritis 
All cases of clinically confirmed SRMA seen at the the small animal neurology service, 
University of Glasgow Small Animal Hospital (UGSAH) between May 2006 and May 
2008  were  prospectively  included  in  this  study.    Dogs  with  a  history  of  steroid 
administration prior to accession were excluded from the study.  Diagnosis was based on 
supportive clinical signs, history, and CSF characteristics (total nucleated cell count > 5 
white blood cells/mL, total protein concentration > 25 mg/dL, and differential cell count). 
 
2.1.1.2  Idiopathic Epilepsy (Negative Controls) 
During the same time period cases of IE seen at the the small animal neurology service, 
University of Glasgow Small Animal Hospital (UGSAH) were prospectively included as 
negative controls in this study (i.e. non-inflammatory CNS disease).  Dogs with a history 
of steroid administration prior to accession were excluded from the study. 
 
2.1.1.3  Meningoencephalitis of Unknown Aetiology (Positive 
Controls) 
All cases of clinically confirmed meningoencephalitis of unknown aetiology (MUA) seen 
at the the small animal neurology service, University of Glasgow Small Animal Hospital 
(UGSAH) between May 2006 and May 2008 were prospectively included in this study as 
positive  controls  (i.e.  inflammatory  CNS  disease).    Dogs  with  a  history  of  steroid 
administration prior to accession were excluded from the study. 
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2.1.1.4  Steroid  Responsive  Meningitis-Arteritis  Relapse 
Cases 
All on-going cases of SRMA that suffered putative relapse of SRMA between May 2006 
and May 2008 were also prospectively included.  These dogs previously been clinically 
confirmed to have SRMA prior to the commencement of this study using the same criteria 
as described above.  Diagnosis of putative relapse was achieved in the same manner to 
presentation although response to treatment was an additional inclusion criterion in these 
cases. 
 
2.1.2  Investigation of cases 
The signalment was recorded and a detailed history was obtained in each case, including 
the duration of clinical signs prior to investigation.  Each dog was subjected to a complete 
general and neurological examination by a veterinary neurologist as detailed by Oliver and 
others (2004).  The examination was performed according to a standardised prospective 
protocol and the investigation was done according to an agreed protocol. 
 
2.1.2.1  Minimum Database 
Routine haematological and biochemical evaluation was performed in all cases to rule out 
the possibility of concurrent systemic disease and as a pre-anaesthetic appraisal of general 
health.  Red blood cell counts, haematocrit, haemoglobin concentration, mean corpuscular 
volume, mean cell haemoglobin, platelet count and total and differential white blood cell 
counts were determined.  Plasma concentrations of urea, creatinine, sodium, potassium, 
chloride, calcium, phosphate, glucose, cholesterol, bilirubin, alkaline phosphatase, alanine 
transferase,  aspartate  transferase,  creatinine  kinase,  total  protein,  albumin  and  globulin 
were  analysed.    Results  of  these  tests  were  compared  to  reference  ranges  of  UGSAH 
laboratories  and  were  used  to  ensure  that  no  other  concurrent  diseases  were  present.  
Identification of concurrent disease was an exclusion criterion in this study.  Results of 
immunoglobulin A and acute phase protein assays were not used as inclusion criteria to 
select cases. 
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2.1.2.2  Steroid Responsive Meningitis-Arteritis Group 
Further diagnostic procedures were performed in SRMA cases in order to rule out other 
potential causes of the clinical signs.  A minimum database for each dog consisted of the 
following: complete blood count (CBC), serum biochemistry profile, orthogonal cervical 
radiographs and CSF analysis (collected from the cerebromedullary cistern) of cytology 
and total protein.  The  diagnosis  was based on signalment, clinical signs, history, and 
supportive  CSF  characteristics  (increased  total  nucleated  cell  count  [TNCC]  >5  white 
blood cells/µL and total protein concentration >25 mg/dL including differential count).  
Diagnostic investigation of cases where the clinical or neurological findings indicated the 
possibility of a different underlying disease also included polymerase chain reaction for 
infectious diseases and MRI to rule-out other diseases. Therefore MRI was not performed 
in those cases with a clinical presentation consistent with SRMA. 
 
2.1.2.3  Idiopathic Epilepsy Group 
In dogs with IE a diagnosis was formed based upon age (between 6 months and 6 years), a 
normal  inter-ictal  general  clinical  and  neurological  examination,  a  normal  minimum 
database (CBC and serum biochemistry including a bile acid stimulation test), negative 
serology  and/or  polymerase  chain  reaction  for  infectious  diseases  (Neosporosis, 
Toxoplasmosis  and  canine  Distemper  virus),  normal  CSF  analysis  (total  nucleated  cell 
count  <5  white  blood  cells/µL  and  total  protein  concentration  <25  mg/dL  including 
differential count) and normal magnetic resonance imaging of the brain.  Exclusion of both 
extra-cranial and intra-cranial causes for seizures supported a diagnosis of IE (Smith et al., 
2008). 
 
2.1.2.4  Meningoencephalitis of Unknown Aetiology Group 
Diagnostic  procedures  for  cases  of  MUA  consisted  of  physical  and  neurologic 
examination, complete blood examinations, magnetic resonance imaging, and examination 
of CSF.  In the absence of histopathological confirmation of MUA, a diagnosis was based 
upon  multifocal  CNS  involvement  on  magnetic  resonance  imaging,  inflammatory  CSF 
analysis (total nucleated cell count >5 white blood cells/µL) and response to treatment, i.e. 
complete remission following cessation of long-term immunosuppressive therapy using a   37 
combination of cytosine arabinoside and prednisolone as described by Zarfoss and others 
(2006). 
 
2.1.3  Treatment Protocol 
All  SRMA  dogs  were  treated  with  a  standard  protocol  commencing  with 
immunosuppressive doses of prednisolone (Prednicare, Animalcare Limited, York, UK) 
using a schedule adapted from other studies (Tipold and Jaggy, 1994; Cizinauskas et al., 
2000).  The protocol is based upon the collective experience of Neurologists at UGSAH 
treating SRMA cases and the timings of re-evaluation were decided based on when clinical 
remission is usually expected.  Figure 2:1 describes this treatment regime.  A re-check 
examination  was  scheduled  2  weeks  into  treatment  when  clinical  remission  was 
anticipated.  Clinical remission was defined as the absence of clinical signs in addition to 
an  unperturbed  CSF  analysis.    A  failure  to  achieve  clinical  remission  at  the  re-check 
examination resulted in following the protocol according to figure 2:1 with a second re-
check examination scheduled 2 weeks later.  A failure of the protocol was considered to be 
two consecutive cycles without achieving clinical remission.  Once clinical remission had 
been achieved no further CSF samples were obtained unless relapse was suspected.   38 
 
 
Figure 2:1:  Treatment schedule for canine patients with steroid responsive meningitis-
arteritis  commencing  with  immunosuppressive  doses  of  prednisolone  using  a  schedule 
adapted from other studies (Tipold and Jaggy, 1994; Cizinauskas et al., 2000). BID, twice 
daily; EOD, every other day; PO, per os; SID, once a day.   39 
 
2.1.4  Timings of Sample Collection 
Control Dogs 
Serum and CSF was obtained at initial diagnosis in dogs with IE and MUA. 
 
Steroid Responsive Meningitis-Arteritis Dogs 
Serum  and  CSF  samples  were  collected  at  3  key  stages  in  disease  management: 
presentation, considered as the point of initial diagnosis; remission, taken as 2 weeks into 
treatment when clinical remission (on treatment) was anticipated; and putative relapse, 
defined as the exhibition, during treatment or the six month post-treatment observation 
period, of clinical signs similar to that demonstrated at presentation.  Diagnosis of putative 
relapse was achieved in the same manner to presentation although response to treatment 
was an additional inclusion criterion in these cases.  Serum samples were also obtained at 
resolution, defined as 4 weeks after cessation of therapy without the recurrence of clinical 
signs.    At  presentation,  remission  and  putative  relapse  a  history,  general  clinical  and 
neurological examination, full CBC and biochemistry, serum and CSF IgA concentration 
and  APP  panel  was  obtained  to  exclude  the  possibility  of  concurrent  diseases.    The 
minimum follow-up for each case was six months after cessation of prednisolone based on 
previous studies (Tipold and Jaggy, 1994; Cizinauskas et al., 2000). 
 
Steroid Responsive Meningitis-Arteritis Relapse Dogs 
Serum  and  CSF  samples  were  collected  from  dogs  with  putative  relapse  during  the 
observation  period  that  had  been  previously  diagnosed  with  SRMA  prior  to  the 
commencement of this study.  Immunoglobulin A was not assayed in the serum or CSF of 
these cases. 
 
2.1.4.1  Cerebrospinal Fluid Collection and Analysis 
Cerebrospinal fluid samples were obtained from the cerebellomedullary cistern and the 
samples  were  inspected  for  colour,  consistency,  and  turbidity.    The  cell  counts  were 
determined by a manual cell count using a modified Fuchs Rosenthal haemocytometer and 
total protein concentrations were determined using the sulphosalicylic acid method and 
compared to reference values given by Di Terlizzi and Platt, 2006 (TNCC >5 white blood   40 
cells/µL and total protein concentration >25 mg/dL).  Cytological examination of CSF was 
performed within 30 minutes and a differential count was recorded.  The CSF samples 
were spun down at 1500 g (3000 rpm) for 10 minutes.  The supernatant was pipetted off 
and resuspended in a drop of serum.  A smear was made from this suspension and stained 
using  Diff-Quik  stain  and  the  differential  count  recorded.    Samples  were  stored  in  an 
eppendorf tube at -20 ˚C until assayed. 
 
2.1.4.2  Serum Sample Collection and Analysis 
Serum samples were obtained by collecting whole blood into a 1.5 ml plain tube and the 
sample was left to clot over 10-15 minutes.  The plain tube was then centrifuged at 1500 g 
(3000 rpm) for 10 minutes.  The serum (supernatant) was then pipetted off and placed in an 
Eppendorf tube and these samples were frozen at -20 ˚C until assayed within 30 minutes of 
sampling. 
 
2.1.4.3  Acute Phase Protein Assays 
C-reactive protein (CRP), serum amyloid-A (SAA), alpha-1-acid glycoprotein (AGP) and 
haptoglobin (Hp) were measured in the serum at each stage of the disease process or at first 
diagnosis  in  the  control  dogs.    Values  for  CRP  were  obtained  using  an 
immunoturbidimetric  assay  (Eckersall  et  al.,  1991).    Alpha-1-acid  glycoprotein  was 
measured using a radial immunodiffusion assay (J-Path Inc, Tokyo, Japan) and SAA was 
measured  using  a  commercial  canine  ELISA  kit  (Tridelta  Development  Ltd,  Kildare, 
Ireland)  (Martinez-Subiela  et  al.,  2005).    Haptoglobin  was  assayed  based  on  its 
haemoglobin  binding  capacity  (Eckersall  et  al.,  1999;  Martinez-Subiela  et  al.,  2005; 
Mischke et al., 2007).  The reference range in our laboratory for serum APP concentrations 
based on previous studies was 0.46 - 9.6 mg/L for CRP, 0 - 1 mg/L for SAA, 0.5 - 2.2 
mg/L for Hp and 0.02 – 0.5 µg/L for AGP concentration. All APP assays were performed 
by a commercial laboratory. 
 
2.1.4.4  Immunoglobulin A Assays 
Immunoglobulin A concentration was measured in serum and CSF at each stage of the 
disease  process  (when  available)  using  a  commercial  dog  IgA  ELISA  quantitation  kit   41 
(Bethyl Laboratories, Montgomery, TX) Ninety-six-well polystyrol microtitre plates (Nunc 
Maxisorp,  Basel,  Switzerland)  were  coated  overnight  at  room  temperature  in  a  humid 
atmosphere with a goat antibody against canine IgA (Bethyl Laboratories, Montgomery, 
TX.) diluted 1:750 in sodium carbonate bicarbonate buffer (pH 9.6).  All of the washing 
steps were performed using 0.9 % sodium chloride solution containing 0.5 % Tween-20 
solution and repeated three times.  The coated wells were incubated with CSF and serum in 
duplicates for 90 minutes at room temperature in a humid atmosphere.  Cerebrospinal fluid 
and serum samples were diluted 1:10, 1:100 and 1:1000 in Tris-NaCl solution (0.002 M 
Tris, pH 8.0; 0.5 M sodium chloride; 0.5 Tween-20) and 100 µl of these dilutions were 
used for analysis.  After washing, mouse monoclonal antibody anti canine IgA (Serotec, 
Düsseldorf,  Germany),  diluted  1:100  in  Tris-NaCl  solution,  was  added  for  another  90 
minutes  at  room  temperature  in  a  humid  atmosphere.    Following  further  washing, 
peroxidase-conjugated  donkey  antimouse  IgG  (Dianova,  Hamburg,  Germany;  diluted 
1:2000 in Tris–NaCl) was incubated for 60 minutes.  After washing, the enzyme reaction 
was  triggered  with  100  µL  of  substrate  solution  (0.4  mg/mL  phenylenediamine 
dihydrochloride; 0.4 mg/mL urea hydrogen peroxide; 0.05 M phosphate-citrate, pH 5.0) 
and stopped by adding 50 µL of phosphoric acid.  Standard curves were established using 
serial dilutions (1:4) of a canine serum pool starting with a concentration of 4.4 µL/mL.  
Results were quantified using a computer-assisted ELISA reader (Dynatech, Denkendorf, 
Germany) at 409 nm using the computer software MicroWin (Microtek, Germany).  In the 
control dogs IgA was assayed at first diagnosis in the serum and CSF. The reference range 
from previous studies is 10.9 - 100.1 µg/mL in the serum and 0 - 0.2 µg/mL in the CSF 
(Tipold et al., 1994). 
 
2.1.5  Statistical Analysis 
Categorical variables were described as fractions or percentages, and comparisons among 
them were performed using χ
2 test.  Non-parametric data were described using median and 
range  with  comparisons  between  paired  and  non-paired  samples  performed  using  the 
Wilcoxon–Signed–Rank–test  and  the  Mann–Whitney–U–test  respectively.    Analyses  of 
correlations between the paired variables were performed by calculating Spearman’s rank 
correlation coefficients.  For all comparisons, a P-value of < 0.05 was considered to be 
significant.    All  statistical  analyses  were  performed  using  GraphPad  Prism  version  4 
(GraphPad Software Inc, La Jolla, CA).   42 
 
Chapter III 
 
RESULTS 
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3.1  Results 
3.1.1  Prevalence 
Steroid  responsive  meningitis-arteritis  represented  0.6  %  of  the  University  of  Glasgow 
Small Animal Hospital admissions and 1.6 % of all neurological consultations during the 
studied time period. 
 
3.1.2  Signalment and History 
3.1.2.1  Steroid Responsive Meningitis-Arteritis Group 
A total of 20 SRMA patients were included in this study. Fourteen dogs were male (5/14 
neutered) and 6 were female (6/6 neutered) though this was not statistically significant (P = 
0.074).  The median age at time of presentation was 11 months (range: 5 - 19 months).  
There were dogs of 12 different breeds and a chi-squared test of the data from the two most 
represented  breeds  in  this  study  (Boxers  n  =  4,  and  English  Springer  Spaniels  n  =  4) 
demonstrated  that  there  was  a  significant  over-representation  when  compared  to  the 
expected hospital population during the same period (χ
2 = 147.35, df = 1, P < 0.001).  Two 
Weimaraners and one of each of the following was recorded; beagle, Bernese Mountain 
Dog,  bichon  frise,  border  collie,  cocker  spaniel,  golden  retriever,  Jack  Russell  terrier, 
Labrador, pointer and saluki. 
 
Presentation  –  The median duration of clinical signs was 6.5 days (range: 2 - 60 days). 
 
Remission  –  All dogs had entered clinical remission 2 weeks into treatment on the regime 
described in figure 2:1. 
 
Relapse  –  4/20 dogs suffered putative relapse; all during treatment.  1/4 dogs had 2 
separate putative relapse episodes and only the first suspected relapse event was analyzed 
because there was insufficient data to comment on subsequent relapse events, as there was 
only one instance where this occurred.  All responded to an increase in prednisolone dose 
to 1 mg/kg TWICE DAILY PO for 14 days according to figure 2:1.  Putative relapse 
occurred at a median of 119 days into treatment (range: 74-164 days) and all putatively 
relapsing dogs were reassessed within 3 days of the recurrence of clinical signs.   44 
 
An additional 7 dogs suffered putative relapse during the observation period following a 
previous  diagnosis  of  SRMA.    All  7  patients  had  been  following  a  prednisolone 
montherapy,  although  this  regime  was  not  implemented  in  the  same  strict  prospective 
manner as the 20 patients included in the prospective treatment regime. 
 
3.1.2.2  Idiopathic Epilepsy Group 
A total of 10 dogs with IE were included in this study. Five dogs were male (3/5 neutered) 
and five were  female (3/5 neutered).  The median age at time of presentation was 47 
months (range: 24 - 70 months).  All 10 dogs were of different breeds.  No patient had 
exhibited seizure activity within 72 hours of presentation to the UGSAH. 
 
3.1.2.3  Meningoencephalitis of Unknown Aetiology Group 
Fifteen dogs were diagnosed with MUA during the observation period of this study.  Seven 
dogs were male (5/7 neutered) and eight were female (8/8 neutered).  The median age at 
time of presentation was 60 months (range: 5 - 91 months).  All 10 dogs were of different 
breeds.  A diagnosis of granulomatous meningoencephalomyelitis (GME) was made at 
post-mortem in 9/15 cases.  The remaining dogs (6/15) responded to immunosuppressive 
therapy (combined prednisolone and cytosine arabinoside) that has since been discontinued 
with complete resmission in all 6 patients at the time of writing. 
 
3.1.3  Clinical Signs 
3.1.3.1  Steroid Responsive Meningitis-Arteritis Group 
Presentation  –  All 20 cases presented with cervical pain and lethargy.  16/20 dog were 
inappetant, 12/20 dogs had pyrexia (defined as a rectal temperature greater than 39.5 
oC), 
3/20  presented  with  bilateral  conjunctivitis  and  thoracolumbar  pain  respectively,  2/20 
exhibited proprioceptive deficits in both forelimbs, 1/20 had Horner’s syndrome, and one 
dog had cranial nerve VIII deficits. 
 
Relapse  –  In 4/4 putatively relapsing episodes cervical pain and lethargy were the only 
clinical signs identified.  Pyrexia was not a feature of these dogs. 
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The 7 dogs exhibiting putative relapse with a prior diagnosis fo SRMA all demonstrated 
cervical  pain  and  lethargy.    No  other  clinical  signs  were  present  and  pyrexia  was  not 
observed in these individuals. 
 
3.1.3.2  Meningoencephalitis of Unknown Aetiology Group 
Presentation  –  All 7/15 cases presented with multifocal neurological signs.  8/15 had 
neurological signs attributable to a single neuroanatomical site (Forebrain 3/8; Cerebellum 
3/8; Brainstem 1/8; C1 to C5 1/8).  6/15 were inappetant, 3/15 had pyrexia (defined as a 
rectal temperature greater than 39.5 
oC), and 1/15 had vomiting. 
 
3.1.4  Blood Profiles 
3.1.4.1  Steroid Responsive Meningitis-Arteritis Group 
Presentation  –  A neutrophilic leukocytosis was seen in 17/20 cases at first presentation 
(median: 23.4 x10
9/L, range: 8.4 - 45.7 x10
9/L, reference range: 6 - 12.0 x10
9/L) with band 
cells  seen  in  8/17  patients.    Hypoalbuminemia  was  present  in  11/20  presenting  cases 
(median: 2.75 g/dL, range: 2.3 - 3.2 g/dL, reference range: 2.9 - 3.6 g/dL). 
 
Remission  –  At the time of remission 8/20 dogs exhibited a leukocytosis without a left 
shift (median: 10.6 x10
9/L, range: 5.1 - 18.0 x10
9/L, reference range: 6 - 12.0 x10
9/L) and 
these  same  8  patients  had  hypoalbuminemia  (median:  2.9  g/dL,  range:  2.6  -  3.3  g/dL, 
reference range: 2.9 - 3.6 g/dL). 
 
Resolution  –  The leucogram and serum albumin concentrations were within normal limits 
at the time of resolution. 
 
Relapse  –  A neutrophilic leucocytosis was seen in 3/4 putatively relapsing dogs (median: 
11.0  x10
9/L,  range:  8.2  -  26.8  x10
9/L,  reference  range:  6  -  12.0  x10
9/L)  and 
hypoalbuminemia was present in 2/4 (median: 2.9 g/dL, range: 2.6 - 3.0 g/dL, reference 
range: 2.9 - 3.6 g/dL). 
 
In the dogs suffering putative relapse following a previous diagnosis of SRMA, 3/7 dogs 
had a leucocytosis, though only one of these cases demonstrated a left shift (median: 11.3 
x10
9/L, range: 8.22 – 26.9 x10
9/L, reference range: 6 - 12.0 x10
9/L).   46 
 
3.1.4.2  Meningoencephalitis of Unknown Aetiology Group 
Presentation  –  A neutrophilic leukocytosis was seen in 3/15 cases (median: 8.1 x10
9/L, 
range:  3.7  –  26.5  x10
9/L,  reference  range:  6  -  12.0  x10
9/L)  with  no  band  cells  seen.  
Hypoalbuminemia was present in 3/15 presenting cases (median: 3.3 g/dL, range: 2.4 - 4.1 
g/dL, reference range: 2.9 - 3.6 g/dL). 
 
3.1.5  Cerebrospinal Fluid Analysis 
All samples had red blood cell counts of less than 5 /µL. 
 
3.1.5.1  Steroid Responsive Meningitis-Arteritis Group 
Presentation  –  Total nucleated cell count was increased in 20/20 cases ranging from 25 to 
2500 white blood cells/µL; reference range: < 5 white blood cells/µL (DiTerlizzi and Platt, 
2006).  Total protein concentration was elevated in 15/20 cases with a range of 17–480 mg/dL 
(median:  60  mg/dL;  reference  range:  <  25  mg/dL)  (DiTerlizzi  and  Platt,  2006).    A 
predominantly  neutrophilic  pleocytosis  (>  80  %)  was  identified  in  12/20  dogs  and  a 
predominantly monocytic pleocytosis (> 80 %) was identified in the remaining 8/20 dogs.  
Those dogs in which a predominantly neutrophilic pleocytosis was observed had clinical signs 
for ≤ 7 days (median: 4.5 days; range: 2 - 7 days) and dogs with a predominantly monocytic 
pleocytosis had clinical signs for > 7 days (median: 14 days; range: 10 - 60 days). 
 
Remission  –  Cerebrospinal fluid parameters were within normal limits in 20/20 cases. 
 
Relapse  –  1/4 putatively relapsing dogs exhibited a pleocytosis (median: 0 /µL; range: 0 - 
512 /µL)  and  2/4  exhibited  an  elevated  total  protein  concentration  (median: 25 mg/dL; 
range: 7 - 40 mg/dL). 
 
6/7 putatively relapsing dogs with a previous diagnosis of SRMA exhibited an unperturbed 
CSF analysis (median: 0 /µL; range: 0 - 96 /µL).  Total protein concentration was within the 
reference range in 6/7 (median: 1.8 mg/dL; range: 5 - 38 mg/dL). 
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3.1.5.2  Meningoencephalitis of Unknown Aetiology Group 
Presentation  –  Total nucleated cell count was increased in all 15/15 cases ranging from 24 to 
1000 white blood cells/µL with a median value of 161 white blood cells/µL; reference range: < 
5 white blood cells/µL (DiTerlizzi and Platt, 2006).  Total protein concentration was elevated 
in 15/15 cases with a range of 28–292 mg/dL (median: 68 mg/dL; reference range: < 25 
mg/dL) (DiTerlizzi and Platt, 2006).  A predominantly neutrophilic pleocytosis (> 80 %) was 
identified in 3/15 dogs and a mixed cell pleocytosis was identified in 10/15 dogs.  2/15 had a 
predominantly lymphocytic pleocytosis (> 80 %)  There was no correlation between duration 
of clinical signs and the differential CSF count. 
 
3.1.6  Serum Acute Phase Protein and Immunoglobulin A 
Response 
3.1.6.1  Steroid Responsive Meningitis-Arteritis Group 
Presentation  –  Serum CRP, SAA and Hp concentrations were above the reference range 
in 20/20 dogs (CRP median: 75.2 mg/L, range: 22.4 - 328.9 mg/L, reference range: 1.0 - 
9.6 mg/L; SAA median: 261.5 mg/L, range: 33.5 - 6100.0 mg/L, reference range: 0.0 - 1.0 
mg/L; Hp median: 16.4 g/L, range: 4.6 - 23.8 g/L, reference range: 0.5 - 2.2 g/L).  Alpha-
1-acid glycoprotein was above the reference range in 19/20 cases (median: 0.96 g/L, range: 
0.24 - 3.79 g/L, reference range: 0.02 – 0.5 µg/L).  Immunoglobulin A was increased in the 
serum of 19/20 patients at presentation (median: 480 µg/mL; range: 82.0 - 3530 µg/mL) 
(Figures 3:1, 3:2, 3:3, 3:4 and 3:5). 
 
Remission  –  Serum CRP remained above the reference range in 16/20 dogs but decreased 
significantly when compared to presentation (CRP median: 14.6 mg/L, range: 5.0 - 29.2 
mg/L,  P  <  0.0001)  (Figure  3:1).    Serum  SAA  and  AGP  significantly  decreased  on 
treatment when compared to presentation (SAA median: 0.57 mg/L, range: 0.11 - 57.50 
mg/L, P < 0.0001; AGP median: 0.32 g/L, range: 0.13 - 1.14 g/L, P = 0.0005) (Figures 3:2 
and 3:3).  Haptoglobin concentration remained similar to presentation (median: 15.1 g/L, 
range: 4.5-29.0 g/L, P = 0.9777) (Figure 3:4).  Immunoglobulin A was not significantly 
different  to  presentation  (P  =  0.2079),  although  demonstrated  a  tendency  towards 
increasing over that of presentation with a median of 477 µg/mL (range: 86-3600 µg/mL) 
(Figure 3:5). 
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Resolution  –  Serum CRP decreased significantly when compared to remission and was 
within the reference range in 20/20 dogs at resolution (CRP median: 5.0 mg/L, range: 2.1 - 
9.4 mg/L, P = 0.0001) (Figure 3:1).  Serum SAA, AGP and Hp all significantly decreased 
at disease resolution when compared to remission (SAA median: 0.23 mg/L, range: 0.05 - 
1.65 mg/L, P = 0.0036; AGP median: 0.15 g/L, range: 0.01 - 0.46 g/L, P = 0.0005; Hp 
median:  2.75  g/L,  range:  0.4  -  11.4  g/L,  P  =  0.0001)  (Figures  3:2,  3:3  and  3:4).  
Immunoglobulin A had significantly decreased compared with presentation (P = 0.0001) 
and remission (P = 0.0004) but still remained above the reference range in 15/20 dogs 
(median: 284.2 µg/mL; range: 41 - 2753.7 µg/mL) (Figure 3:5). 
 
Relapse  –  Serum CRP and SAA was increased in 4/4 suspected relapse cases (CRP 
median: 83.7 mg/L, range: 56.2 - 402.0 mg/L; SAA median: 262.8 mg/L, range: 11.6 - 
480.5 mg/L).  Alpha-1-acid glycoprotein was within the reference range in 3/4 (median: 
0.65 g/L, range: 0.62 - 0.93 g/L) and Hp was elevated in all 4/4 patients (median: 18.3 g/L, 
range:  19.0  -  19.8  g/L).    Immunoglobulin  A  was  increased  in  4/4  cases  (median:  463 
µg/mL, range: 406-2597 µg/mL) (Table 3-1). 
 
The serum concentrations of CRP and SAA in dogs with suspected relapse with a previous 
diagnosis of SRMA were at least 7 and up to 10 times greater than the reference range 
respectively (CRP median: 142 mg/L, range: 33 - 407.0 mg/L; SAA median: 408.5 mg/L, 
range: 10.6 – 744.0 mg/L).  Alpha-1-acid glycoprotein was within the reference range in 
4/7 (median: 0.28 g/L, range: 0.01 - 1.38 g/L) and Hp was elevated in all 7/7 patients 
(median: 17.6 g/L, range: 10 – 31.4 g/L) (Table 3-2). 
 
3.1.6.2  Idiopathic Epilepsy Group 
Presentation  –  Serum CRP and SAA concentrations were within the reference range in 
10/10 dogs (CRP median: 7.53 mg/L, range: 5.2 – 9.6 mg/L, reference range: 1.0 - 9.6 
mg/L; SAA median: 0.22 mg/L, range: 0 – 0.67 mg/L, reference range: 0.0 - 1.0 mg/L) 
(figures  3:6  and  3:7).    Haptoglobin  was  above  the  reference  range  in  6/10  cases  (Hp 
median: 3.75 g/L, range: 0 – 8.3 g/L, reference range: 0.5 - 2.2 g/L) (figure 3:8).  Alpha-1-
acid glycoprotein was above the reference range in 3/10 cases (median: 0.47 g/L, range: 
0.12 - 0.92 g/L, reference range: 0.02 – 0.5 µg/L) (figure 3:9).  Immunoglobulin A was 
increased in the serum of 10/10 patients at presentation (median: 383 µg/mL; range: 106 - 
874 µg/mL) (figure 3:10). 
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3.1.6.3  Meningoencephalitis of Unknown Aetiology Group 
Presentation  –  Serum CRP was raised in 13/15 cases (CRP median: 26.2 mg/L, range: 7.1 
– 56.6 mg/L, reference range: 1.0 - 9.6 mg/L) (figure 3:6) and serum SAA was increased in 
9/15 dogs (SAA median: 9.6 mg/L, range: 0.24 – 26.4 mg/L, reference range: 0.0 - 1.0 
mg/L)  (figure  3:7).    9/15  dogs  had  Hp  concentrations  above  the  reference  range  (Hp 
median: 3.0 g/L, range: 0 – 16.2 g/L, reference range: 0.5 - 2.2 g/L) (figure 3:8) and AGP 
was above the reference range in 8/15 cases (median: 0.47 g/L, range: 0.12 - 0.92 g/L, 
reference range: 0.02 – 0.5 µg/L) (figure 3:9).  Immunoglobulin A was increased in the 
serum of 13/15 patients at presentation (median: 396 µg/mL; range: 62 - 2680 µg/mL) 
(figure 3:10).   50 
 
 
 
Figure 3:1:  Serum C-reactive protein (CRP) acute phase response in 20 canine SRMA 
patients at presentation, remission (+14 days on prednisolone treatment) and resolution (4 
weeks after cessation of therapy).  The box represents the 25 – 75
th percentile range, the 
line through represents the median, the range lines correspond to the highest and lowest 
values, outliers are represented by x, and the highest and lowest values of the laboratory 
normal reference range is represented by dashed lines.  Extreme outliers are presented as 
censored data.   51 
 
 
Figure 3:2:  Serum amyloid-A (SAA) acute phase response in 20 canine SRMA patients at 
presentation, remission (+14 days on prednisolone treatment) and resolution (4 weeks after 
cessation of therapy).  The box represents the 25 – 75
th percentile range, the line through 
represents the median, the range lines correspond to the highest and lowest values, outliers 
are represented by x, and the highest and lowest values of the laboratory normal reference 
range is represented by dashed lines.  Extreme outliers are presented as censored data.   52 
 
 
Figure 3:3:  Serum alpha-1-acid glycoprotein (AGP) acute phase response in 20 canine 
SRMA  patients  at  presentation,  remission  (+14  days  on  prednisolone  treatment)  and 
resolution (4 weeks after cessation of therapy).  The box represents the 25 – 75
th percentile 
range, the line through represents the median, the range lines correspond to the highest and 
lowest  values,  outliers  are  represented  by  x,  and  the  highest  and  lowest  values  of  the 
laboratory normal reference range is represented by dashed lines.  Extreme outliers are 
presented as censored data.   53 
 
 
Figure 3:4:  Serum haptoglobin (Hp) acute phase response in 20 canine SRMA patients at 
presentation, remission (+14 days on prednisolone treatment) and resolution (4 weeks after 
cessation of therapy).  The box represents the 25 – 75
th percentile range, the line through 
represents the median, the range lines correspond to the highest and lowest values, outliers 
are represented by x, and the highest and lowest values of the laboratory normal reference 
range is represented by dashed lines.   54 
 
 
Figure 3:5:  Serum immunoglobulin A (IgA) response in 20 canine SRMA patients at 
presentation, remission (+14 days on prednisolone treatment) and resolution (4 weeks after 
cessation of therapy).  The box represents the 25 – 75
th percentile range, the line through 
represents the median, the range lines correspond to the highest and lowest values, outliers 
are represented by x, and the highest and lowest values of the laboratory normal reference 
range is represented by dashed lines.  Extreme outliers are presented as censored data.   55 
 
 
Figure 3:6:  A comparison of the serum C-reactive protein (CRP) acute phase response in 
three  groups  of  dogs  suffering  from  steroid  responsive  meningitis-arteritis  (SRMA), 
idiopathic  epilepsy  (IE)  and  meningoencephalitis  of  unknown  aetiology  (MUA) 
respectively.  The box represents the 25 – 75
th percentile range, the line through represents 
the  median,  the  range  lines  correspond  to  the  highest  and  lowest  values,  outliers  are 
represented by x, and the highest and lowest values of the laboratory normal reference 
range is represented by dashed lines.  Extreme outliers are presented as censored data.   56 
 
 
Figure 3:7:  A comparison of the serum amyloid-A (SAA) acute phase response in three 
groups of dogs suffering from steroid responsive meningitis-arteritis (SRMA), idiopathic 
epilepsy (IE) and meningoencephalitis of unknown aetiology (MUA) respectively.  The 
box represents the 25 – 75
th percentile range, the line through represents the median, the 
range lines correspond to the highest and lowest values, outliers are represented by x, and 
the highest and lowest values of the laboratory normal reference range is represented by 
dashed lines.  Extreme outliers are presented as censored data.   57 
 
 
Figure 3:8:  A comparison of the serum haptoglobin (Hp) acute phase response in three 
groups of dogs suffering from steroid responsive meningitis-arteritis (SRMA), idiopathic 
epilepsy (IE) and meningoencephalitis of unknown aetiology (MUA) respectively.  The 
box represents the 25 – 75
th percentile range, the line through represents the median, the 
range lines correspond to the highest and lowest values, and the highest and lowest values 
of the laboratory normal reference range are represented by dashed lines.   58 
 
 
Figure 3:9:  A comparison of the serum alpha-1-acid glycoprotein (AGP) acute phase 
response  in  three  groups  of  dogs  suffering  from  steroid  responsive  meningitis-arteritis 
(SRMA), idiopathic epilepsy (IE) and meningoencephalitis of unknown aetiology (MUA) 
respectively.  The box represents the 25 – 75
th percentile range, the line through represents 
the  median,  the  range  lines  correspond  to  the  highest  and  lowest  values,  outliers  are 
represented by x, and the highest and lowest values of the laboratory normal reference 
range is represented by dashed lines.  Extreme outliers are presented as censored data.   59 
 
 
Figure  3:10:    A  comparison  of  the  serum  immunoglobulin  A  (IgA)  response  in  three 
groups of dogs suffering from steroid responsive meningitis-arteritis (SRMA), idiopathic 
epilepsy (IE) and meningoencephalitis of unknown aetiology (MUA) respectively.  The 
box represents the 25 – 75
th percentile range, the line through represents the median, the 
range lines correspond to the highest and lowest values, outliers are represented by x, and 
the highest and lowest values of the laboratory normal reference range is represented by 
dashed lines.  Extreme outliers are presented as censored data.   60 
 
IgA (µg/mL)  Relapse 
Patient 
Signalment 
at Relapse 
Dose of 
prednisolone 
at relapse 
Serum  CSF 
CRP 
(mg/L) 
Serum 
SAA 
(mg/L) 
Serum 
AGP 
(g/L) 
Serum 
Hp 
(g/L) 
Serum 
1  18 month 
old FN 
Labrador 
0.5 mg/kg 
EOD 
460  0.81  83  117  0.62  19.2 
2  13 month 
old ME 
Jack 
Russell 
Terrier 
0.5 mg/kg 
SID 
406  0.63  84.4  408.5  0.62  19.8 
3  13 month 
old ME 
Boxer 
0.5 mg/kg 
every 3rd day 
2597  4.87  402  11.6  0.72  18.3 
4a  10 month 
old  MN 
Springer 
Spaniel 
0.5 mg/kg 
EOD 
465  0.76  56.2  480.5  0.93  19.0 
4b  15 month 
old  MN 
Springer 
Spaniel 
0.5 mg/kg 
EOD 
357  0.62  69.6  0.4  0.43  21.4 
 
Table 3-1:  Serum and cerebrospinal fluid (CSF) concentrations of immunoglobulin A 
(IgA) and serum concentrations of C-reactive protein (CRP), serum amyloid-A (SAA), 
alpha-1-glycoprotein  (AGP),  and  haptoglobin  (Hp)  in  putatively  relapsing  steroid 
responsive meningitis-arteritis dogs. Regarding patient 4, ‘a’ denotes the first relapse event 
and ‘b’ represents a second relapse event. EOD, every other day; FN, female neutered; 
ME, male entire; MN, male neutered; SID, once a day.   61 
 
Signalment  Serum CRP 
(mg/L) 
Serum SAA 
(mg/L) 
Serum AGP 
(g/L) 
Serum Hp (g/L) 
1 year old ME 
Saluki 
33  480.5  0.93  10 
9 month old FN 
Labrador 
83.3  116.5  0.76  14 
1 year old FN 
Golden 
Retriever 
341  744  0.13  12.5 
16 month old 
MN Boxer 
84.4  408.5  1.38  17.6 
9 month old ME 
Jack Russell 
Terrier 
142  56  0.28  31.4 
18 month old  
FN Springer 
Spaniel 
407  10.6  0.22  18.2 
9 month old FN 
Boxer 
247.3  475.2  0.01  27.2 
13 month old 
ME Boxer 
33  480.5  0.93  10 
1 year old ME 
Weimaraner 
83.3  116.5  0.76  14 
 
Table 3-2:  Serum concentrations of C-reactive protein (CRP), serum amyloid-A (SAA), 
alpha-1-glycoprotein  (AGP),  and  haptoglobin  (Hp)  in  putatively  relapsing  steroid 
responsive meningitis-arteritis dogs diagnosed prior to the start of this study.  FE, female 
entire; FN, female neutered; ME, male entire; MN, male neutered.   62 
 
3.1.7  Cerebrospinal Fluid Immunoglobulin A Response 
3.1.7.1  Steroid Responsive Meningitis-Arteritis Group 
Presentation  –  The IgA concentration in CSF was elevated above the reference range in 
19/20 patients (median: 0.69 µg/mL; range: 0.15 - 4.67 µg/mL; reference range: 0.0 - 0.2 
µg/mL) (Figure 3:11). 
 
Remission  –  The IgA concentration in CSF was increased above the reference range in 
20/20 patients (median: 0.62 µg/mL; range: 0.28 - 3.24 µg/mL; reference range: 0.0 - 0.2 
µg/mL) (Figure 3:11). 
 
Relapse  –  The IgA concentration in CSF was increased above the reference range in 4/4 
putatively relapsing patients (median: 0.79 µg/mL; range: 0.63 - 4.87 µg/mL) (Table 3-1). 
 
3.1.7.2  Idiopathic Epilepsy Group 
Presentation  –  The IgA concentration in CSF was elevated above the reference range in 
8/10 patients (median: 0.53 µg/mL; range: 0.11 – 1.23 µg/mL; reference range: 0.0 - 0.2 
µg/mL) (Figure 3:12). 
 
3.1.7.3  Meningoencephalitis of Unknown Aetiology Group 
Presentation  –  The CSF IgA concentration was increased above the reference range in 
15/15 patients (median: 0.84 µg/mL; range: 0.22 – 1.92 µg/mL; reference range: 0.0 - 0.2 
µg/mL) (Figure 3:12).   63 
 
 
Figure 3:11:  Cerebrospinal fluid immunoglobulin A (IgA) response in 20 canine steroid 
responsive  meningitis-arteritis  patients  at  presentation  and  remission  (+14  days  into 
prednisolone  treatment).    The  box  represents  the  25  –  75
th  percentile  range,  the  line 
through represents the median, the range lines correspond to the highest and lowest values 
and outliers are represented by *.  Extreme outliers are presented as censored data.  The 
highest  and  lowest  values  of  the  laboratory  normal  reference  range  is  represented  by 
dashed lines (Tipold and Jaggy, 1994).   64 
 
 
Figure 3:12:  A comparison of the cerebrospinal fluid immunoglobulin A (IgA) response 
in  three  groups  of  dogs  suffering  from  steroid  responsive  meningitis-arteritis  (SRMA), 
idiopathic  epilepsy  (IE)  and  meningoencephalitis  of  unknown  aetiology  (MUA) 
respectively.  The box represents the 25 – 75
th percentile range, the line through represents 
the  median,  the  range  lines  correspond  to  the  highest  and  lowest  values,  outliers  are 
represented by x, and the highest and lowest values of the laboratory normal reference 
range is represented by dashed lines.  Extreme outliers are presented as censored data.   65 
 
3.1.8  Statistical Comparisons Between Groups 
3.1.8.1  Acute Phase Proteins 
Serum  CRP  was  significantly  different  between  all  three  disease  groups  at  first 
presentation (SRMA versus IE, p < 0.0001; IE versus MUA, p = 0.0002; SRMA versus 
MUA, p < 0.0001; figure 3:6).  Serum SAA was also significantly different between all 
three disease groups at first presentation (SRMA versus IE, p < 0.0001; IE versus MUA, p 
=  0.0007;  SRMA  versus  MUA  p  <  0.0001;  figure  3:7).    Serum  Hp  was  significantly 
different when comparing the SRMA dogs with IE or MUA (p < 0.0001; figure 3:8) but 
was not significantly different when comparing the IE group with dogs diagnosed with 
MUA (p = 0.8678; figure 3:8).  Alpha-1-acid glycoprotein was only significantly different 
when comparing the SRMA group to the IE group at first presentation (p = 0.0024; figure 
3:9). 
 
3.1.8.2  Immunoglobulin A 
Serum  and  CSF  IgA  were  not  significantly  different  between  any  of  the  three  disease 
groups studied at first presentation (Serum: SRMA versus IE, p = 0.2620; IE versus MUA, 
p = 0.9779; SRMA versus MUA, p = 0.3954; CSF: SRMA versus IE, p = 0.1527; IE 
versus MUA, p = 0.0214; SRMA versus MUA, p = 0.3861;  figure 3:10). 
 
3.1.9  Correlation Analyses 
Serum CRP demonstrated a significant positive correlation with the CSF TNCC (r = 0.902, 
P < 0.001). 
 
3.1.10 SRMA Treatment Protocol 
All 20 dogs responded to the six-month course of prednisolone therapy.  Four dogs were 
suspected to suffer from putative relapse with 1/4 having two separate episodes.  All 4/4 
suspected  relapse  dogs  remained  within  the  treatment  protocol  and  increasing  the 
prednisolone dose as described resulted in resolution of clinical signs with a six-month 
long follow-up period off treatment (clinical resolution). 
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Side-effects of prednisolone therapy were recorded at the first re-check examination.  The 
most  commonly  reported  side-effects  at  this  stage  were  diarrhoea  (n=14), 
polyuria/polydipsia (n=13), weight gain (10/20) and polyphagia (n=6).  All reported side-
effects resolved following the reduction as described in the treatment regime (Figure 2:1).   67 
CHAPTER IV 
 
DISCUSSION 
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4.1  Discussion 
Inflammatory diseases of the CNS are one of the most common causes of neurological 
dysfunction in the dog (Fluehmann et al., 2006).  The antemortem diagnosis of canine 
inflammatory CNS disease remains challenging being based on a combination of clinical 
criteria,  non-specific  laboratory  investigations  and  exclusion  of  other  diseases.  
Cerebrospinal fluid analysis appears superior to other diagnostic modalities in reaching a 
diagnosis (Tipold, 1995) and surprisingly supersedes magnetic resonance imaging (MRI) 
in sensitivity (Lamb et al., 2005; Bohn et al., 2006).  However, the true sensitivity and 
specificity of CSF analysis in inflammatory CNS disease has not been determined given 
the difficulties in obtaining a definitive diagnosis in every case (Lowrie et al., 2008).  In 
addition normal CSF parameters have been described in a number of histopathologically-
confirmed inflammatory CNS diseases (Thomas and Eger, 1989; Demierre et al., 2001; 
Cherubini et al., 2006; Tipold and Jaggy, 1994; Cizinauskas et al., 2000).  These features 
of inflammatory disease are reflected in SRMA in that it is a relatively common disease 
(representing 2% of neurological referrals in one study; Flehmann et al., 2006), with no 
definitive diagnostic test (Tipold and Jaggy, 1994), and infrequently causes disease without 
CSF perturbations (Tipold and Jaggy, 1994; Cizinauskas et al., 2000). 
 
This thesis describes a series of 20 dogs with SRMA with respect to response to therapy, 
long-term  outcome,  and  expression  of  potential  disease  markers  at  milestones  in 
management.  A comparison is made of each of these markers to determine their value at 
the various stages of this disease and an investigation is performed into their expression in 
other inflammatory and non-inflammatory CNS diseases.  In order for inclusion into this 
study the SRMA patients had to present with typical historical and clinical signs of SRMA, 
a CSF pleocytosis and exclusion of other disease.  In the unlikely event that the presenting 
clinical  signs  were  related  to  a  different  underlying  disease,  patients  were  furthermore 
excluded if they developed other disease (unrelated to SRMA) within the period of at least 
six  months  post-treatment.    Findings  of  this  prospective  study  demonstrate  that 
prednisolone monotherapy is successful at achieving resolution of SRMA. 
 
In this study all dogs presenting with SRMA were under two years old.  This finding is not 
unexpected  as  it  is  reported  that  dogs  can  develop  an  age-resistance  to  the  disease  at 
approximately two years of age (Scott-Moncrieff et al., 1992).  Previous SRMA studies 
have reported older patients wih a diagnosis of SRMA.  For example, Tipold and Jaggy   69 
(1994) report a dog of seven years old and Cizinauskas and others (2000) report ten dogs 
with SRMA of which 2/10 were over 24 months of age.  Therefore although age would 
give an indication as to the likelihood of SRMA it cannot be used as an exclusion criterion. 
 
Clinical signs previously reported in SRMA include pyrexia, depression, anorexia, neck 
pain,  stiff  gait,  conjunctivitis,  tonsillitis,  hyperaesthesia  of  the  ribs,  postural  reaction 
deficits of the limbs, hypermetria, and a decreased menace response (Tipold and Jaggy, 
1994; Cizinauskas et al., 2000).  These signs can vary according to time and a comparison 
between  studies  is  difficult,  as  this  would  compare  individuals  at  different  stages  of 
disease.  In this study cervical pain and lethargy was the most common finding and was 
present in all cases of SRMA reported.  Then in decreasing order of representation, other 
signs  included  inappetance,  pyrexia,  bilateral  conjunctivitis,  thoracolumbar  pain, 
proprioceptive  deficits  in  the  forelimbs,  Horner’s  syndrome,  and  cranial  nerve  VIII 
deficits.  On this basis, cervical pain and lethargy were suggestive in the diagnosis of 
SRMA although these signs are non-specific and common to other diseases, including non-
inflammatory and non-neurological diseases, making them non-specific. 
 
Two forms of the disease have been reported; a fulminating acute form characterised by a 
neutrophilic pleocytosis, and a chronic protracted form represented by a mild mononuclear 
or mixed cell pleocytosis associated with neurological deficits reflecting extension of the 
inflammation to contiguous structures (e.g. a myelitis or encephalitis) (Tipold and Jaggy, 
1994).  In a retrospective study investigating inflammatory and infectious diseases of the 
CNS  it  was  found  that  although  CSF  perturbations  were  non-specific  for  a  particular 
disease they were 88% sensitive at detecting the presence of intrathecal inflammation or 
infection (Tipold, 1995).  Additionally, SRMA patients frequently had extremely high total 
nucleated cell counts and this feature was shared with bacterial meningitis (an extremely 
rare cause of inflammatory CNS disease; Radaelli and Platt, 2002) and the occasional case 
of GME.  Therefore CSF analysis is non-specific and although the magnitude of nucleated 
cells in the CSF may give an indication of the disease process it is important to use this test 
in combination with other clinical indices and to exclude other causes of a pleocytosis.  
The acute form of SRMA, characterised as a neutrophilic pleocytosis (Tipold and Jaggy, 
1994), was observed in 12/20 SRMA dogs presented in this study; these cases having 
clinical signs ≤ 7 days duration.  The 8/20 remaining SRMA cases in this study had a 
monocytic pleocytosis and were reported to have exhibited clinical signs for > 7 days with 
4/8 demonstrating additional neurological deficits.  However, these 8 cases of mononuclear   70 
pleocytosis  do  not  share  all  the  characteristics  of  the  protracted  form  of  SRMA  as 
described by Tipold and Jaggy (1994). 
 
The chronic form of SRMA can be difficult to distinguish from meningoencephalitis of 
unknown aetiology and for this reason raised serum and CSF IgA concentrations have been 
suggested to be a suitable marker for differentiation of these diseases (Tipold and Jaggy, 
1994).  The literature on IgA demonstrates that an increased concentration may be found in 
the  serum  and  CSF  of  SRMA  patients  though  this  feature  is  shared  with  other 
inflammatory central nervous system (CNS) diseases giving it a low specificity (Tipold 
and Jaggy, 1994; Tipold et al., 1994; Tipold et al., 1995)
 and the extent of the normal range 
for serum IgA may vary with breed (Griot-Wenk et al., 1999).  The sensitivity of this 
combination, in contrast, is reported to be as high as 100 % (Tipold and Jaggy, 1994) and 
this study found 19/20 cases had increased serum and CSF IgA at presentation (95 % 
sensitivity)  supporting  this  figure  and  giving  this  immunoglobulin  diagnostic  value  in 
SRMA.  Furthermore serum and CSF IgA remained elevated in 20/20 patients at remission 
and serum IgA remained elevated in 15/20 dogs at disease resolution despite remaining 
asymptomatic for the six month post-treatment observation period.  Although a humoral 
immune response is initiated in SRMA the reason for this persistently raised intrathecal 
and systemic IgA is not known
 (Schwartz et al., 2008). 
 
Acute phase proteins are serum proteins produced predominantly by the liver in response 
to  bacterial  infection,  trauma,  neoplasia,  tissue  infarction,  and  immune-mediated 
inflammatory disease and as such are non-specific (Cerón et al., 2005).  Serum CRP and 
SAA correlate with the clinical course of SRMA with relatively increased concentrations at 
diagnosis and a resolution of clinical signs being associated with normal to mildly elevated 
serum concentrations.  Their production is not reported to be affected by corticosteroids 
with  the  exception  of  Hp  which  is  known  to  increase  in  concentration  with  high-dose 
prednisolone therapy and this supports the results of the present study (Martinez-Subiela et 
al., 2004, Cerón et al., 2005). 
 
In contrast to a previous study (Bathen-Noethen et al., 2008) serum CRP demonstrated a 
significant positive correlation with the TNCC of CSF (r = 0.902, P < 0.001).  Also in 
contrast  to  the  same  study,  serum  CRP  remained  above  the  reference  range  in  16/20 
SRMA dogs at the time of remission, despite an unperturbed CSF analysis in 20/20 SRMA 
cases.    However,  it  should  be  noted  that  there  is  a  difference  in  timing  of  the  first 
assessment between the two studies (2 weeks vs 4 weeks on therapy) that makes a direct   71 
comparison difficult.  The current study suggests that initial immunosuppressive doses of 
prednisolone suppress but do not eliminate inflammation in dogs affected by SRMA as 
serum CRP remains elevated but markers of inflammation in the CSF (TNCC and total 
protein) are resolved.  This is in keeping with the concept that CRP is a more sensitive 
marker of inflammation than more traditional markers e.g. peripheral neutrophilia (Cerón 
et al., 2005). 
 
Serum amyloid-A was raised at least 30 times above the reference range in all presenting 
SRMA cases and occasionally was found to be orders of magnitude greater than the normal 
range.  This appears to be a unique observation to this canine inflammatory disease.  Given 
the  large-scale  production  of  SAA,  hepatic  synthesis  is  the  most  likely  source  of  this 
protein.    However,  extra-hepatic  intrathecal  or  vascular  production  of  SAA  cannot  be 
excluded  by  these  results  and  further  studies  are  required  to  elucidate  the  site(s)  of 
synthesis. 
 
Serum  Hp  was  found  to  remain  elevated  during  treatment  of  SRMA  in  keeping  with 
previous studies that found Hp was induced by steroid medication (Cerón et al., 2005; 
Martinez-Subiela et al., 2004), but also supports its use in investigation prior to steroid 
administration.  In inidividual cases Hp concentrations were found to increase or decrease 
during therapy, and this probably reflects the conflicting influence of disease resolution 
versus steroid induction in these patients.  Alpha-1-acid glycoprotein concentrations were 
above the reference range at initial presentation of SRMA in 19/20 dogs.  However, there 
was a tendency towards higher concentrations of this protein in those patients that had 
shown clinical signs for >7 days.  These patients also had a predominance of monocytes 
(>80%) in the CSF.  This observation would agree with findings in other species where 
AGP has found to be particularly associated with chronic conditions (Horadagoda et al., 
1999; Eckersall et al., 2007). 
 
Occasionally SRMA can have an atypical presentation in which traditional CSF parameters 
(TNCC  and  total  protein  concentration)  may  be  unperturbed  or  exhibit 
albuminocytological dissociation.  Such observations have been reported in the protracted 
form of the disease (Tipold and Jaggy, 1994; Cizinauskas et al., 2000) and in cases of 
putative relapse (Cizinauskas et al., 2000; Lowrie et al., 2008).  In the present study 3/4 
putatively  relapsing  dogs  had  a  normal  TNCC  and  2/4  had  normal  total  protein 
concentrations.  A further seven dogs with a previous diagnosis of SRMA demonstrated 
putative relapse during the observation period of which 6/7 patients had a normal TNCC   72 
and total protein concentration.  A diagnosis was made in these cases based on a previous 
recent diagnosis of SRMA, clinical signs similar to those at initial diagnosis, raised serum 
and  CSF  IgA  concentrations,  increased  serum  APP  concentrations,  and  response  to 
treatment.    A  neutrophilic  leucocytosis  was  also  seen  in  3/4  putatively  relapsing  dogs 
enrolled on the treatment protocol and 4/7 suspected relapse patients previously diagnosed 
with SRMA.  Although this may be a manifestation of the effect of steroids, these dogs 
lacked the hallmarks of a steroid-induced leucogram; notably concomitant lymphopenia, 
eosinopenia or right shift (Raskin et al., 1999).  Indeed in the presence of unperturbed CSF 
parameters (2/4 and 6/7 putative relapsing cases) and a normal leucogram (4/4 and 4/7 
putative  relapsing  cases),  CRP  and  SAA  were  found  to  be  elevated  in  all  patients 
exhibiting clinical signs consistent with SRMA relapse.  The literature demonstrates that 
1/32 dogs (Tipold and Jaggy 1994) and 1/6 dogs (Cizinauskas et al., 2000) with suspected 
SRMA relapse did not show an elevated CSF cell count.  The elevated APP concentrations 
in these cases, though unspecific for SRMA, suggested the presence of an inflammatory 
disease, which in the clinical context was considered to support the diagnosis of relapse.  
Re-starting or increasing the dose of prednisolone in these patients resulted in remission 
with a full recovery in all cases.  All putative relapse cases had a minimum follow-up of 6 
months and did not develop any concurrent diseases. 
 
Cerebrospinal  fluid  analysis  is  considered  the  gold  standard  ante-mortem  diagnostic 
modality in confirming CNS inflammation (Tipold, 1995).  A novel observation in this 
study  was  the  identification  of  an  apparently  inflammatory  environment  (raised  serum 
APPs) in the presence of an unperturbed CSF analysis at clinical remission of SRMA.  In 
this study it was difficult to prove whether or not raised systemic APPs truly represented 
an inflammatory CNS environment.  However, a recent report demonstrated increased IL-6 
concentrations  in  unperturbed  CSF  samples  taken  from  putatively  relapsing  SRMA 
patients providing preliminary evidence that CNS/meningial inflammation may be present 
without a pleocytosis  (Lowrie et al., 2008).  Twelve percent of CSF samples obtained 
from  188  dogs  with  inflammatory  or  infectious  CNS  disease  were  within  the  normal 
reference  ranges  for  total  nucleated  cell  count  and  total  protein  concentration  (Tipold, 
1995).  The presence of an apparently inflammatory CNS environment in the absence of 
CSF  perturbations  is  recognised  in  the  veterinary  literature,  in  particular  it  has  been 
associated with histopathologically confirmed cases of GME (Thomas and Eger, 1989; 
Dermierre et al., 2001; Cherubini et al., 2006), but the reason for unperturbed CSF remains 
elusive.  These circumstances make diagnosis challenging and so the availability of other 
markers of inflammation are of value in these rare circumstances.   73 
 
The diagnostic utility of IgA and APPs was also examined in this study by comparing the 
synthesis of these proteins in inflammatory and non-inflammatory CNS diseases.  Serum 
IgA was found to be increased above the reference range (Tipold et al., 1994) in 13/15 
MUA  cases,  10/10  IE  dogs  and  19/20  SRMA  cases.    Cerebrospinal  fluid  IgA 
concentrations were above the published reference range (Tipold et al., 1994) in 15/15 
MUA cases, 8/10 IE dogs and 19/20 SRMA cases.  Statistical comparison of serum and 
CSF  IgA  concentrations  did  not  reveal  any  significant  differences  between  the  three 
different disease groups.  The combination of increased serum and CSF IgA concentrations 
is reported to have a specificity of 83 to 100 % (Tipold and Jaggy, 1994; Tipold et al., 
1995; Maiolini et al., 2009).  Although the sensitivity of combined raised serum and CSF 
IgA concentrations was high for SRMA (95 %) in this study, the specificity was low when 
using the calculations described by Lamb (2007).  The specificity of raised serum and CSF 
IgA  concentrations  to  correctly  diagnose  SRMA  in  our  population  of  dogs  with 
inflammatory CNS disease (SRMA and MUA) was 13 %.  This specificity decreased to 8 
% when considering the diagnostic utility of IgA in SRMA in the study population as a 
whole.  In contrast to this study, the sensitivity of combined raised serum and CSF IgA 
concentrations in diagnosing SRMA in a group of 12 Boxers with the disease was 25 % 
(Behr and Cauzinille, 2006).  A recent report of histopathologically confirmed SRMA in a 
Boxer also reported normal serum and CSF IgA concentrations (Wrzosek et al., 2009).  
These results suggest that IgA concentrations in the serum and CSF are influenced by 
multiple  extraneous  sources.    Griot-Wenk  and  others  (1999)  have  demonstrated  that 
genetic factors may influence serum IgA concentration.  The discovery of raised serum and 
CSF IgA in SRMA was made on dogs from Switzerland (Tipold et al., 1994).  The study 
reporting a 25 % sensitivity of this combination in SRMA was performed on patients from 
France.  The current study was performed on dogs from the United Kingdom.  All three 
geographical  areas  appear  to  harbour  dogs  with  a  wide  range  of  serum  and  CSF  IgA 
concentrations, regardless of breed.  The lack of a ‘true’ control population in this study is 
a limitation and the original reference range was determined on a group of 15 healthy 
laboratory Beagles (Tipold et al., 1994). 
 
Serum  CRP  was  found  to  be  increased  above  the  reference  range  in  20/20  dogs  with 
SRMA and 13/15 with MUA.  Serum SAA was elevated in 20/20 dogs with SRMA and 
9/15 patients with MUA.  Serum CRP and SAA were within the reference range in all 10 
dogs with  IE.  Statistical comparison of serum CRP and SAA concentrations revealed 
significant differences between all three different disease groups.  C-reactive protein and   74 
SAA are described as fast APPs responding rapidly to inflammation and its resolution 
(Cerón et al., 2005).  SRMA and MUA both share the clinicopathological features of acute 
inflammation that presumably drives this APR.  However, CRP and SAA were statistically 
different between these two groups demonstrating a difference in the magnitude of this 
response  between  the  two  conditions.    Meningioencephalitis  of  unknown  aetiology  is 
considered a chronic inflammatory CNS disease charcterised by chronic and coexisting 
acute  inflamamtory  meningeal  and  parenchymal  lesions  (Cordy,  1979;  Braund,  1985; 
Munana et al., 1998; Higgins et al., 2008).  In contrast SRMA more frequently presents in 
its  acute  form  with  meningeal  pathology  alone  (Harcourt,  1978;  Meric  et  al;.,  1985).  
Patients with IE did not appear to have raised serum CRP or SAA concentrations. 
 
Haptogolobin  and  AGP  are  considered  more  moderate  APPs  and  as  such  they  are 
considered responsive to more chronic conditions (Horadagoda et al., 1999; Eckersall et 
al.,  2007).    AGP  concentrations  were  above  the  reference  range  in  a  proportion  of 
individuals from all three groups of dogs.  Meningoencephalitis of unknown aetiology is a 
chronic  inflammatory  CNS  disease  and  so  increases  in  these  proteins  would  not  be 
surprising (Cordy, 1979; Braund, 1985; Munana et al., 1998; Higgins et al., 2008).  An 
APR has been described in humans with epilepsy although this is transient and associated 
with seizure activity (Peltola et al., 2002).  The precise nature of this response is unknown 
and  may  relate  to  neuronal  injury  (Correale  et  al.,  1998)  or  the  seizure  activity  itself 
(Peltola et al., 2002).  All patients with IE in this study had been seizure free for > 72 hours 
and this may explain the observation of a ‘moderate’ APR in the absence of CRP and SAA 
elevations.  Another explanation is the observation that phenobarbitone induces AGP in the 
dog  (Bai  and  Abramson,  1983)  and  all  10  pateints  in  this  study  were  receiving 
phenobarbitone at doses sufficient to achieve a therapeutic concentration.  A limitation of 
the current study is the lack of a true negative control group (i.e. healthy dogs) although the 
published  literature  provides  reference  ranges  for  IgA  and  serum  APPs  on  which  to 
interpret the results. 
 
The design of the protocol is derived from the collective experience of Neurologists based 
at UGSAH over several years combined with guidelines from previous studies (Tipold and 
Jaggy, 1994; Cizinausakas et al., 2000).  The idea was to design a protocol that would be 
simple to follow and easy to understand so that the owner and veterinary surgeon alike, 
would always know the process involved in obtaining complete resolution.  In doing this 
the protocol was the first to incorporate a regime to manage suspected relapse cases and 
therefore  each  patient  was  treated  uniformly  with  regards  to  medciation  when  this   75 
complication arose.  This is the first study to cater for relapse patients, offering a rigid 
management  regime  to  which  they  can  adhere.    In  the  event  of  this  protocol  failing 
(defined  as  two  consecutive  cycles  without  achieving  clinical  remission)  then  other 
medications may be of benefit in treating SRMA, however, this was not necessary in the 
20 patients recruited in this study. 
 
The follow-up period of 6 months was based on observations on the pattern of relapse in 
previous studies (Tipold and Jaggy, 1994; Cizinausakas et al., 2000).  With the wealth of 
immunosuppressive  therapy  available  in  veterinary  medicine  today  there  is  a  tendency 
towards multi-modal therapy in the management of inflammatory CNS disease.  In this 
case series a prednisolone monotherapy protocol for SRMA was successful at achieving 
full remission in 20/20 affected dogs, with an in protocol case relapse rate of 20% (4/20).  
In contrast Cizinauskas and others (2000) report full remission in 8/10 dogs receiving a 
prednisolone based treatment regime with an in protocol case relapse rate of 60%; the 
treatment regimen included the use of other therapeutic agents.  Consequently only 4/10 
cases  received  prednisolone  monotherapy.    Of  these  ten  cases  one  was  euthanased  for 
reasons related to the disease.  Tipold and Jaggy (1994) describe a managed prednisolone 
monotherapy protocol, involving adjustment of the prednisolone dose in the light of CSF 
parameters, achieving a case relapse rate of 25 %, resolution rate of 60 % and a 5 % 
mortality.  It should be borne in mind that the two case series referred to and the current 
study are likely to contain a differing spectrum of the stages of SRMA at the time of 
presentation, which may influence the response of the cohort to therapy.  It is reported that 
long-term prednisolone to treat SRMA is associated with mild clinical side-effects and this 
study  mirrors  these  findings,  with  diarrhoea  being  the  most  commonly  occurring  side-
effect (Cizinauskas et al., 2000).  Our findings support the use of an immunosuppressive 
prednisolone monotherapy, using the described protocol, in the treatment of SRMA. 
 
In order to most effectively manage a patient with SRMA it would be of value to identify a 
parameter that would predict the potential for relapse.  It has been observed that dogs that 
go  onto  exhibit  more  than  one  relapse  have  a  tendency  towards  higher  serum  CRP 
concentrations  after  4  weeks  on  immunosuppressive  prednisolone  therapy  (Bathen-
Noethen et al., 2008).  In this study assessment of clinical and laboratory parameters did 
not identify any obvious modality for predicting relapse.  However, a direct comparison 
between  these  studies  is  inappropriate  as  re-check  examinations  were  scheduled  at 
different time points during treatment.  However, the present study confirms that relapse 
has  a  propensity  to  occur  on  treatment  and  not  following  cessation  of  treatment  in   76 
agreement with a previous study (Cizinauskas et al., 2000).  Only first relapse events were 
analysed in this study, however inclusion of the single second relapse event did not alter 
the outcome of the statistical tests for any of the parameters and therefore inclusion or 
exclusion of these results do not bias our data. 
 
4.2  Summary 
The described prednisolone monotherapy resulted in resolution of SRMA in 20/20 cases with a 
disease free post treatment interval of at least six-months.  Remission of clinical signs was 
associated  with  an  unperturbed  CSF  analysis  in  the  presence  of  elevated  serum  CRP 
concentrations.  Serum AGP and Hp support initial diagnosis alone.  In contrast to APPs, 
serum IgA remains elevated at remission and resolution suggesting different aspects of the 
disease  are  reflected  by  these  different  markers.    Therefore  serum  and  CSF  IgA 
concentrations  aid  in  initial  diagnosis  but  are  not  a  marker  of  clinical  remission  or 
resolution  of  disease.    Immunoglobulin  A  is  elevated  in  other  inflammatory  and  non-
inflammatory CNS diseases of the dog.  A robust prognostic indicator at initial presentation 
for potential relapse remains elusive.  This study has suggested that the traditional markers 
of CNS inflammation, i.e. CSF TNCC and total protein concentration, are not sensitive in 
all circumstances of inflammatory CNS disease and serum APPs may offer clinical utility 
in aiding a diagnosis when other diseases have been ruled-out.   77 
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